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ABSTRACT 
A MINIMALLY INVASIVE ASSAY 
DETECTS BRCA1 AND BRCA2 PROTEIN TRUNCATIONS 
INDICATIVE OF THE PRESENCE OF 
A GERMLINE MUTATION 
SEPTEMBER 2000 
TIMOTHY J. BYRNE, B.S. UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Wesley R. Autio 
Family members with a heritable mutation in the BRCA1 or BRCA2 gene have 
up to an 85% life-long risk of contracting one or more of the cancers associated with a 
genetic alteration to these genes. The inheritance risks of a BRCA alteration to first and 
second-degree relatives of affected individuals are 50% and 25%, respectively. 
Currently, members from high-risk families can be tested for the presence of BRCA 1 or 
BRCA2 mutations by gene sequencing of blood cell DNA. This test is expensive and 
generally is not reimbursed by insurance carriers. 
Over 85% of BRCA 1 and BRCA2 mutations are reported to result in the 
production of a truncated protein, from which the carboxy terminal end sequences ot their 
respective protein is missing. 
In preliminary studies, using antibodies specifie for the amino acid terminal or the 
carboxy terminal ol the BRCA1 protein, we demonstrated that immunohistochemical 
analysis of surgical specimens, consisting of matched ovarian tumor and normal 
uninvolved tissue, identified BRCA1 protein truncations in two matched samples. Each 
BRCA1 protein truncation was shown to be indicative of the presence of a BRCA1 
germline mutation. 
Human buccal cells were then investigated as a minimally invasive cell source for 
this assay. Buccal cells were shown to express BRCA1 and BRCA2 protein 
immunohistochemically using distinct antibodies for the BRCA1 and BRCA2 protein 
terminals. Transcription of the BRCA1 and BRCA2 gene within buccal cells was also 
shown to occur by RT-PCR. 
A double blind study was then conducted using blood DNA and buccal cells 
collected from thirteen high-risk patients for carrying a germline BRCA1 or BRCA2 
mutation. Mutation analysis (PCR, SSCP, and gene sequencing) was performed on 
DNA. Immunohistochemical analysis for the BRCA1 and BRCA2 protein was 
performed on cytospun deposited buccal cells. The buccal cell assay correctly predicted 
the presence of six germline BRCA1 mutations, three germline BRCA2 mutations, and 
three with no mutations. One predicted germline BRCA2 mutation did not correlate with 
DNA sequencing results. Based on these results, this assay exhibited a 100% negative 
predictive value and 90% positive predictive value. 
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CHAPTER 1 
OVERVIEW AND REVIEW OF LITERATURE 
1.1 Overview 
Family members with a heritable mutation in the BRCA1 or BRCA2 gene have 
up to an 85% life-long risk of contracting one or more of the cancers associated with a 
genetic alteration to these genes. Many types of carcinomas are associated with the loss 
of normal function of these two genes. BRCA1 and BRCA2 share similarities and 
differences with respect to location and tissue where these malignancies develop. Both 
genes are strongly associated with breast, ovarian and prostate cancer. However, 
increased risk for colon cancer is associated with BRCA1 only. Male breast cancer, 
pancreatic cancer, laryngeal cancer, hepatocellular cancer and ocular melanoma are 
associated with BRCA2. The risk for contracting each of these types of cancer varies 
greatly. For first degree female relatives (mother, sisters, daughters) carrying the same 
gene mutation, there is an 85% lifetime risk for breast cancer, 26%-85% risk of 
developing ovarian cancer, and a four-fold increased risk of developing colon cancer. 
Other cancers that have been associated with BRCA mutations require further study to 
ascertain the cancer risk conferred by each. 
The inheritance risks of a BRCA alteration to first and second-degree relatives of 
affected individuals are 50% and 25%, respectively. Currently, members from high-risk 
families can be tested for the presence of BRCA1 or BRCA2 mutations by gene 
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sequencing of blood cell DNA. This test is expensive. The current cost is approximately 
$l,200/gene for each family member, and generally is not reimbursed by insurance 
carriers. 
Over 85% of BRCA1 and BRCA2 mutations are reported to result in the 
production of a truncated protein, from which the terminal end sequences (i.e. carboxy 
terminus, C-terminus) of their respective protein is missing (6, 17, 35, 36). These gene 
mutations are in the form of insertions, single base alterations, single base deletions, or 
multiple base deletions that cause a frame shift that results in a premature stop codon. 
The premature stop codon produces truncation of the protein consequent to the presence 
of the gene mutation. 
Amino acid sequencing of the BRCA1 and BRCA2 proteins, deduced from the 
availability of the gene sequence, has allowed for the development of peptide sequences. 
These peptide sequences have been used as immunogens to raise a series of antibodies 
capable of detecting specific regions of the BRCA1 or BRCA2 protein. 
In preliminary studies, using antibodies specific for the amino acid terminal or the 
carboxy terminal of the BRCA1 protein, we demonstrated that immunohistochemical 
analysis of surgical specimens, consisting of matched ovarian tumor and normal 
uninvolved tissue, identified BRCA1 protein truncations in two matched samples. Each 
BRCA1 protein truncation was also shown to be indicative of the presence of a BRCA1 
germline mutation. 
Human oral buccal cells provide a non-invasive source of normal nucleated cells 
that express the BRCA1 and BRCA2 protein. Heritable BRCA mutations are contained 
within every nucleate cell. 
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Buccal cells are easily collected with a cotton swab, deposited in a liquid medium 
by the test subject and transferred to the research laboratory for testing. 
This immunohistochemical test is based on the hypothesis that cells of a BRCA1 
or BRCA2 germline mutation carrier will express differences in antibody reactivity of 
one or both terminal regions of a BRCA protein. Non-germline mutation carriers will 
not. An imbalance between the end terminus regions, as measured by differences in 
antibody reactivity, would be indicative of a truncated protein possibly resulting from a 
gene alteration. 
1.1.1 Hypothesis 
The hypothesis of this study was that carriers of a BRCA1 or BRCA2 germline 
mutation that results in a truncated BRCA1 or BRCA2 protein, could be detected by 
conducting immunohistochemical analysis of the BRCA1 or BRCA2 protein using 
buccal cells collected from their oral mouth cavity. 
To test this hypothesis a double blind study was conducted using 
immunohistochemical analysis of buccal cells and genetic analysis of cell DNA. Buccal 
cell samples and peripheral blood were collected from patients selected from the genetic 
counseling services at Baystate Medical Center in Springfield, Massachusetts, following 
their signed consent. Thirteen high-risk individuals with a significant family history of 
breast and/or ovarian cancer were studied. 
Immunohistochemical analyses of BRCA1 and BRCA2 were conducted on 
cytospin deposited buccal cells using antibodies directed against their respective N- 
terminal and C-terminal amino acids. 
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Mutation analysis was conducted using single stranded conformational 
polymorphism (SSCP). Using this technique, gel electrophoresis showed differences in 
gene sequences by alterations in single stranded DNA migration patterns. This was 
followed by gene sequencing of all coding exons for BRCA1 and/or BRCA2 in which 
polymorphisms were detected. In some instances, direct gene sequencing was conducted 
by commercial laboratories. Results from genetic analysis and immunohistochemical 
analysis were then compared. 
1.1.2 Objective 
The objective of this study was to develop an inexpensive, minimally invasive 
method to screen individuals for BRCA1 and BRCA2 germline mutations to identify all 
members of these families, males and females, who may be at risk for passing a heritable 
mutation to their offspring. 
1.2 Literature Review 
1.2.1 Epidemiology of BRCA1 and BRCA2 
It is estimated that over 200,000 women develop breast or ovarian cancer in the 
United States annually (1). Of these, 5%-10% (10,000-20,000 cases annually) will be 
caused by mutations in either the BRCA1 or BRCA2 gene (2). Extensive studies of 
breast cancer families as well as of breast and ovarian cancer families have resulted in 
the isolation of these two genes (3,4). Both BRCA1 and BRCA2 have been 
independently linked with heritable breast and/or ovarian cancer (3,5) and have also been 
associated with one or more of the following cancers: colon, prostate, pancreatic, 
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laryngeal, hepatocellular, and ocular melanoma (13, 14, 67, 92, 93, 94, 95,101,115, 116). 
The mutated forms of these genes do not directly cause cancer, but confer an increased 
risk of cancer development. It is generally believed that these genes act as tumor 
suppressor genes, and that alterations of both maternal and paternal alleles for either one 
of these genes is required for the development of cancer (Knudson two hit hypothesis, 6). 
Individuals with a heritable BRCA1 or BRCA2 gene mutation carry one copy of the 
altered form of this gene in every nucleated cell of their body. Such individuals may 
develop cancer if the corresponding normal BRCA allele is altered within a specific 
tissue (breast, ovary, colon, prostate, etc.). Individuals with a germline mutation are one 
"hit" closer to developing cancer than the population at-large. Because of this, 
individuals with germline BRCA1 or BRCA2 mutations tend to be younger at age of 
diagnosis, and are more likely to experience multiple primary tumors involving several 
organ systems (e.g. bilateral disease, or primaries involving colon, breast and/or ovaries). 
Families with BRCA1 or BRCA2 gene mutations represent 80- 90% of all cancer 
family syndromes associated with breast and/or ovarian cancer (62-66). First-degree 
female relatives (mother, sisters, daughters) of gene carriers are at 50% risk of carrying 
the same gene mutation. Female mutation carriers have up to an 85% lifetime risk of 
developing breast cancer, 26%-85% risk of developing ovarian cancer, and a four-fold 
increased risk of developing colon cancer (BRCA1) (63-66). Male carriers with a 
mutated BRCA1 gene are at increased risk of developing colon and prostate cancer, and 
male breast cancer for those with a BRCA2 mutation (2). Other associated cancers may 
place males and/or female carriers at modestly elevated risk relative to the general 
population (65, 66). 
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Recently, several studies have investigated the role of BRCA1 and BRCA2 gene 
mutations in seemingly sporadic breast or ovarian cancer as well as the prevalence of 
BRCA mutations in specific populations. These studies show that individuals with 
sporadic disease are more likely to carry a germline (heritable) BRCA gene mutation if 
they are: 1. younger age at diagnosis (<45 years of age at diagnosis of ovarian cancer, 
<40 years of age at diagnosis of breast cancer); 2. if they have bilateral disease or, 3. if 
they are of Ashkenazi Jewish ancestry (6-16). Two studies have demonstrated that 
approximately 2% of the Ashkenazi Jewish population carry a BRCA1 mutation (16-20). 
In addition, BRCA1 gene alterations have been detected in approximately 50% of 
ovarian cancers, although only a fraction of these cancers are heritable in nature (17-19). 
1.2.2 Pathology Of Breast Cancer Tumors In Germline BRCA Mutation Carriers 
The pathology of breast cancers in predisposed women differs from that of 
sporadic cases. Differences also exist between carriers of germline BRCA1 and BRCA2 
mutations. In general BRCA 1-associated breast cancers have been reported as highly 
proliferating tumors (53). Correlation between mutation type and disease phenotype has 
also been reported for another autosomal dominant condition, neurofibromatosis type 2 
(106). In this study, symptoms were most severe when there was a truncation mutation. 
The majority of heritable BRCA1 and BRCA2 mutations result in protein truncations 
within the conserved terminal regions of their respective proteins. These have also been 
categorized as highly proliferative tumors (56, 74, 82, 83, 85, 91, 94). This tumor type 
segregates as a genetic trait in BRCA families (53, 54) and also shows a strong 
genotype-phenotype correlation. Within BRCA-mutation carriers, breast tumors 
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removed from BRCA1 mutation carriers showed greater pleomorphism and higher 
mitotic count than similar tumors derived from carriers of a BRCA2 mutation (56, 82, 
83, 85, 91, 94). These findings suggest that breast cancers due to BRCA1 mutations 
have a different natural history and possible disease progression than cancers due to 
BRCA2 mutations or apparent sporadic forms of cancer. This would allow for 
identification based upon visual differences (34, 54 
1.2.3 Molecular Biology Of Tumors From Germline BRCA Mutation Carriers 
Studies of tumors removed from patients with germline BRCA1 or BRCA2 
mutations are reported to display loss of heterozygousity (LOH) (7, 26, 27, 29, 30, 57, 
118-121). Many times LOH reportedly occurs at the locus that encodes the cystein rich 
RING finger motif which binds zinc, as well as at other highly conserved domains (12, 
56, 41, 70). Zinc-binding domains are defined as a series of cysteine and histidine 
residues and are believed to mediate protein-protein and protein-DNA interactions. 
These investigators suggested that BRCA products play a role as tumor suppressor 
genes. Other studies support this hypothesis by showing that BRCA1 negatively 
regulates the proliferation of mammary epithelial cells (58) and is involved in 
differentiation in multiple tissues in response to ovarian hormones (56). Adding to this 
evidence are reports showing that both genes encode nuclear and cytoplasmic proteins 
with cell cycle-regulated expression patterns that colocalize in multiple tissues during 
proliferation and cell differentiation (82). 
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1.2.4 Common Features of BRCA1 and BRCA2 
BRCA1 and BRCA2, while appearing sequentially unrelated structurally, have 
much in common: a translational start-site for each gene is located in exon 2; exon 11 
contains over 50% of the codons for the amino acid sequence; and both genes code for 
an exceptionally large, highly charged protein (3). BRCA1 codes for 1863 amino acids 
and BRCA2 codes for 3418 amino acids. Comparison of the amino acid sequence of 
human BRCA1 and BRCA2 to the amino acid sequence of these same genes in mouse, 
indicates that the respective proteins share approximately 60% identity between these 
two species (70, 71, 74). Because most tumor-suppressor genes are more highly 
conserved across species than BRCA1 and BRCA2, this suggests that both genes may be 
evolving at the same rate. 
Both BRCA messages also appear to be induced during the late G1 early S phase 
of the cell cycle (52, 58, 76, 77, 90), with concordant expression of the protein (47, 80, 
81). Another similarity was noted in a study of expression patterns for each of these 
proteins in developing mouse embryos. Both BRCA1 and BRCA2 are most highly 
expressed in rapidly dividing tissues undergoing differentiation. 
Up-regulation of the steady-state level of both messages was also reported in 
breast tissue during puberty, pregnancy and lactation (56, 74, 82, 83, 85, 91). However, 
BRCA1 and BRCA2 mRNA expressions are differentially regulated by sex hormones. 
When testosterone levels increased in the testes, up-regulation of BRCA2 was delayed 
relative to BRCA1. In the breast, ovarian hormones caused an increase in BRCA1 
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mRNA only, with no effect observed on BRCA2 (82). Still, the many commonalities 
shared by these two genes indicate that they may function in the same or overlapping 
biological pathways. 
1.2.5 Molecular Biology and Functional Properties of BRCA1 and BRCA2 
1.2.5.1 Granin-Like Properties 
The discovery that the BRCA1 protein exhibits properties of a family of proteins 
called granins gave researchers clues to some possible BRCA1 functions and provided 
conceptual ideas for studying the location of the BRCA1 protein within the cell. Granins 
are a secreted protein located in secretory granules of neuroendocrine tissues, some of 
which are estrogen regulated (59, 60, 61, 68). Other post-translation granin 
characteristics are protein modification by sulfation, glycosylation or phosphorylation 
and peptide activation following proteolytic cleavage (60, 61). 
It does not seem the case, however, that BRCA1 functions exclusively as a granin. 
There are also discrepancies in the literature concerning the BRCA1 protein size and 
cellular location. Two separate research teams report the BRCA1 protein to be a 
190KDa. regulated, secretory protein (50, 51). In one of these reports the BRCA1 
protein's functional mechanism is referred to as unique for tumor suppressor gene 
products (51). Other investigators report that the BRCA1 protein is a 220KDa, nuclear, 
phosphoprotein (46, 47,49, 52). The greatest expression and phosphorylation of 
BRCA1 reportedly occurs in the S and M cell phases (47, 48). While similar antibodies 
were used in all of these investigations (C20, D20, OP92, OP93), differences 
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in results were explained by cross reactivity with estrogen growth factor receptors 
(EGFR), aberrant subcellular localization (48) and different fixation techniques (45). 
Another study reports finding that BRCA1 expression is indirectly responsive to 
estrogen resulting from mitogenic activity (52). This would be inconsistent with a 
hormonally regulated granin. We tested buccal cells for cross reactivity with EGFR and 
found none. This showed that buccal cells do not contain EGFR and allowed us to 
consider these cells as a viable test source. The antibodies used in this study are similar 
to those used in previous reports. 
1.2.5.2 Transcriptional-Regulation and BRCA1 and BRCA2 
Many studies of the BRCA1 and BRCA2 genes have concentrated on mitotic 
transcription and translation aspects to determine how and where BRCA product(s) 
function on the cellular level. Both BRCA1 and BRCA2 contain putative transcription 
activation domains. In BRCA2 a region encoded by exon 3 contains a 45-amino acid 
portion with similarities to a transcription factor c-jun, known to activate transcription in 
yeast when fused to the lexA DNA-binding domain (107, 108). A COOH terminus in 
BRCA1 has been reported as a binding module for GAL4 required for transcription of 
the GAL reporter gene (90, 99). Studies with knockout mice (mice with specific, 
engineered gene deletions) revealed that loss of Brcal or Brca2 regulation results in 
overexpression of gene p21 and/or gene p53. This resulted in death during early 
embryonic development (87, 117). This study clearly suggests that the BRCA genes 
may control cell growth and prevent cell proliferation by actions that regulate 
transcription and/or translation of other gene products. 
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An in vivo study found that an interaction occurred between the N-terminal region 
of the BRCA1 protein and a second protein referred to as BARD1. Much homology to 
conserved domains near the BRCA1 protein's C-terminal was found in the BARD1 
protein. This consisted of a COOH-terminal domain present as two tandem repeats 
termed BRCT (96-98). Missense mutations that segregate with a predisposition to breast 
cancer were shown to disrupt the BRCA1-BARD1 interaction. These mutations are 
associated with disruption of the RING finger structural motif as well (55). This 
suggests that protein interaction may be important for BRCA1-mediated tumor 
suppression. All these studies place emphasis on the importance of the BRCA1 and 
BRCA2 termini regions and their continued integrity for proper protein functioning. The 
evolutionary conserved nature of these regions has been shown to hold for other 
mammals as well (12). This too, argues for their importance in mammary cell growth 
and would allow for greater specificity in their detection. 
1.2.5.3 DNA Repair Involves BRCA1 and BRCA2 
Initially, high levels of expression patterns of the hRAD51 protein along with both 
BRCA1 and BRCA2 in testes, ovaries and thymus (82, 83), all areas important for 
meiosis and recombination, suggested that BRCA genes may be involved in DNA 
damage response. While BRCA1 and BRCA2 now clearly appear to play important 
roles in cellular response to DNA damage, each does so through different pathways. 
BRCA2 is reported to interact directly with hRAD51. This protein catalyzes ATP- 
dependent DNA strand exchange reactions and is one of five known human homologs of 
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the prototypical E. coli recombination and repair protein RecA (113, 117). The area on 
BRCA2 that is responsible for this is located on exon 11. This domain consists of 8 or 9 
copies of a 30-80 amino acid repeat termed BRC (72). 
This area has been highly conserved relative to the rest of the BRCA2 sequence, 
suggesting that the BRC region is important for normal functioning (73). 
In mouse studies, various mutations within this area have resulted in phenotypic 
differences in disease expression. When coding sequence were deleted upstream of all 
suspected putative interaction domains, all mice died while still in the embryonic stage 
(87, 109, 110). Mice with mutations that disrupted a small portion, 3 repeats, (112) or 
large portion of this region, 6 repeats, (111) survived to birth and past weaning. Mice 
with fewer functional repeats exhibited defects that include absence of germ cells, 
stunted growth and increased risk of lymphoma. 
Although these studies were conducted in mice, they still elucidate the significance 
of the BRCA2-hRAD51 (MmRad51 in mice) interaction domain. By contrast, BRCA1 
reportedly does not interact directly with hRAD51, although both BRCA1 and hRAD51 
may be present in the same multiprotein complex. In mitotic cells BRCA1, hRAD51 and 
BRCA2 co-localize to discrete nuclear foci during the S phase, whereas in meiotic cells, 
this protein complex associates with axial elements along developing synaptic complexes 
(38, 86, 89, 88, 114,). These data suggest that this protein complex may be the activation 
of double-break repair and/or homologous recombination. BRCA1 appears to function 
in the DNA repair mechanism by direct association with the RNA polymerase II 
transcriptional apparatus known as a holoenzyme. Although the role that BRCA1 plays 
here is not clearly defined, holoenzymes are intimately involved with many DNA repair 
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elements (38, 101). Also, within the carboxy-terminal region of BRCA1 a TP53 binding 
region referred to as BRCT has been identified. BRCT repeats are conserved motifs 
found in many proteins and are reportedly involved with DNA repair and metabolism 
(70, 71). This domain was found to be important for substrate interaction to allow 
activation of the GAL gene (90, 99). Collectively, these data are interpreted to support a 
transcriptional role for BRCA1 in DNA repair. These studies also indicate the BRCA 
genes are directly and indirectly involved with production and activation of other 
proteins that play additional regulatory roles in cell growth and differentiation. 
1.2.5.4 Splice Variants and BRCA1 
Recent efforts directed toward molecular characterizations of BRCA1 have found 
functional BRCA1 splice variants in mRNA and protein products. This may help 
explain some differences in protein localization reported in the literature and also 
suggests that each gene has multiple functions. Splice variants have been found in exon 
11 and 9+10. Each is predicted to encode an 80-85KDa BRCA1-derived protein (44). 
Through RNA probe titration and RT-PCR, (reverse transcription-polymerase chain 
reaction) BRCA1 and a BRCA1 splice variant, delta-1 lb, have been shown to be co¬ 
expressed in many cells, however, the splice variant of BRCA1, delta 1 lb however, is 
reduced or absent in several breast and ovarian tumor lines. This has been interpreted to 
suggest that each protein has a distinct role in regulating cell growth (43). Other splice 
variants have also been characterized and indicate cytoplasmic and nuclear localization 
(42). Results from this same study also suggest that transcriptional factors coupled to 
phosphorylation by complexes associated with the zinc RING finger domain are 
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necessary for major protein-protein BRCA1 interactions (42). Mutations in the RING 
finger domain may prevent cell cycle regulation, allowing for cell proliferation. 
Aprelikova et al. (37) showed that BRCA1 protein levels did not change with the 
addition or deprivation of growth factor in cell line MCF10A. This suggests that 
BRCA1 may have an indirect role in cell cycle regulation of some cell lines. With this 
assay test, some splice variants may give false negatives. Approximately 15% of 
reported mutations do not result in protein truncation. This could occur by mutations 
contained within the removed portions while both protein-end terminals remain intact. 
In this study, this possibility was taken into consideration by using SSCP and gene 
sequencing to verily all immunohistochemical results. 
1.2.5.5 Mutations In BRCA1 and BRCA2 
While high frequencies of specific mutations in each gene have been found in 
certain ethnic populations (6), the vast majority of mutations reported to date are 
distributed over their whole coding sequences. In BRCA1, over 100 mutations have been 
identified. This list includes missense mutations, frameshifts and splice-site alterations 
(2, 7). In BRCA 2, however, the majority of mutations described involve microdeletions 
of 1-6 nucleotides that have resulted in missense and ffameshift mutations only (4). This 
large assortment of mutations, coupled with the formidable size of each of these genes 
(BRCA 2 spans approximately 70 kb of genomic DNA; BRCA 1 is distributed over 100 
kb, 4, 7), makes detection of mutations and gene sequencing very labor intensive, 
expensive and technically challenging. 
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In many male breast cancer patients, BRCA2 germline mutations are found in 
families without a history of the disease (67, 102-105). In this study, 34 male breast 
cancer cases were analyzed. Seven were found to contain germline BRCA2 mutations 
and only one of these seven cases had a positive family history. 
A few identified cancer families have been linked to the BRCA1 gene region 
without any BRCA1 mutations being found. This suggests some form of disruption of a 
regulatory nature that affects normal transcription and/or translation. The presence of a 
RING finger (zinc-binding) domain near the amino terminal of BRCA1 supports this 
theory (12, 56, 41). This type of protein conformation is a binding site that is associated 
with regulating DNA transcription (12, 56). 
Three BRCA1 regions have been identified as potential nuclear localization 
signals. Transport through the nuclear pore complex requires a nuclear localization 
sequence(s) (NLS) in the transport substrate. Mutations induced to each region revealed 
two putative regions that resulted in cytoplasmic localization of the BRCA1 protein (40). 
This supports the possibility that defects in the cellular pathways involving NLS can 
result in mislocation of the BRCA1 protein and disrupt transcriptional regulation of other 
genes. 
In a separate study, the C-terminal region comprising exons 16-24 of BRCA1, 
called BRCT, was reported to bind to a specific DNA domain of the GAL reporter gene. 
These binding proteins activate transcription of the GAL gene from promoters 
containing a specific GAL4 site located on BRCA1 (39). This function was suppressed 
when a clinically introduced missense mutation caused loss of the wild-type 
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BRCA1-BRCT domain (90, 99). Mislocation of the BRCA proteins resulting from 
defects in the cellular pathway may not be detected immunohistochemically but would 
have been elucidated in our study using SSCP and gene sequencing. 
Many germline mutations that interrupt protein binding are clinically relevant 
because of their implications on the transcriptional process and protein production. This 
greatly broadens the regulatory functions for the BRCA1 and BRCA2 protein. The 
categorizing of cause and effect for specific BRCA mutations will allow for a better 
understanding of their roles on the cellular level and how cancers associated with a 
disfiinctional BRCA1 or BRCA2 gene can develop. 
One feature common to most BRCA1 and BRCA2 mutations is that they produce a 
truncated protein that results from a premature stop codon in the amino acid sequence. 
Immunohistochemical analysis of normal (non-tumor) tissue from carriers of this type of 
mutation could reveal a quantitative decrease in carboxy terminal antibody binding 
relative to quantitative antibody binding to the amino terminal (figure 1). A similar 
assay performed on muscle biopsies has been shown to have useful clinical applications 
in distinguishing between truncated dystrophin protein products associated with 
Duchenne's muscular dystrophy and Becker's muscular dystrophy, which contain an 
untruncated form of the same protein. 
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a) * * *—<AA -CCC>— * * * 
♦ * —<AAA-CCC>—* * * 2A/2C 
b) ***—<AAA-CCC>—*** 1A/1C 
[ [0] ] 
C) ***—<AAA-CCO—*** 2A/1C 
*♦*—<aaa-X 
d) ***—<AAA-X 1A/0C 
[ [0] ] 
or 
***—<AAA-X 
***—<AAA-X 2A/0C 
or 
[0]/[0] 0A/0C 
Figure 1. Diagrammatic representation of anti-BRCAl antibody binding in various 
conditions, (a) Antibody binding pattern expected in tissue with two unaltered BRCA1 
proteins (i.e. no mutations), (b) Antibody binding pattern expected in tissue in which the 
protein of an entire BRCA1 allele has been lost (i.e. tissue or tumor in which the allele is 
lost or in which an unstable protein product is produced), (c) Antibody binding pattern 
expected in tissue in which one normal allele is present and the other allele contains a 
nonsense mutation that produces a stable protein product (i.e. normal tissue with a germline 
nonsense mutation or tumor with a sporadic nonsense mutation), (d) Antibody binding 
pattern expected in tissue in which one allele contains a nonsense mutation and the other 
allele is deleted or in which the second allele contains a different nonsense mutation (i.e. 
tumor of individual in lc, or tumor following two sporadic hits) or in which no stable 
product is produced. ***—< and >—*** represent immunohistochemically detectable 
antibodies directed against the normal amino and carboxy terminal amino acids of BRCA1, 
respectively. AAA and CCC represent the normal amino and carboxy terminal ends of 
BRCA1, respectively. X represents a nonsense mutation. [ 0 ] represents an absent protein 
product. The expected relative antibody binding ratios are depicted to the right. 
1.2.5.6 Testing For Germ line BRCA Mutations 
The determination of BRCA1 and BRCA2 gene status among high-risk individuals 
has generated much interest. Such identification can potentially help triage individuals 
from families with known or suspected BRCA mutations into appropriate screening and 
management protocols and can assist in enhancing knowledge about this disease. 
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The demonstration of a heritable BRCA1 or BRCA2 gene mutation among at-risk 
individuals can result in more specific targeting of expensive screening and intervention 
protocols. 
Individuals from families with known or suspected BRCA mutations, who 
themselves have not demonstrated germline mutations, can be spared the cost and 
morbidity associated with such protocols and returned to surveillance protocols more 
consistent with those individuals' specific risk factors. For individuals with heritable 
BRCA mutations, such testing can help better define the natural history of this disease, 
as well as the efficacy of current surveillance protocols and the benefit of prevention 
regimens, and also may lead to the development of more effective screening, prevention, 
and treatment strategies (2). 
In light of these potential benefits, testing for BRCA genes has become 
commercially available for individuals considered at increased risk (>10%) for carrying 
a germline BRCA gene mutation. Unfortunately, the complexity of both the BRCA1 and 
BRCA2 genes and the paucity of common mutations has hindered the development of a 
simple assay for mutation detection. 
Current commercial and investigative methods for mutation analysis include 
sequencing of candidate polymorphisms detected by single-strand conformation 
polymorphism (SSCP) analysis, clamped denaturing gel electrophoresis, or heteroduplex 
analysis, direct DNA sequencing of the BRCA1 and/or BRCA2 genes, protein truncation 
tests with surgical samples, and DNA chip technology (20). These techniques are 
expensive to develop, are labor intensive, and/or require substantial technical expertise. 
As a result, the cost of commercial testing is prohibitive ($1200 for the analysis of one 
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gene, $2400 for the analysis of both BRCA1 and BRCA2 genes). In the absence of an 
inexpensive screening tool, the development of cost-effective clinical protocols for 
individuals at risk for a BRCA gene mutation remains a substantial challenge with 
significant benefits to humankind. 
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CHAPTER 2 
AN ANTIBODY-BASED ASSAY DETECTS BRCA1 MUTATIONS IN 
SURGICAL SPECIMENS OF PAIRED OVARIAN TUMORS AND 
UNINVOLVED NORMAL TISSUE 
2.1 Overview 
Breast and ovarian cancers rank second and fourth, respectively, in mortality in 
the United States with greater than 200,000 new cases reported each year. A significant 
number of these cases can be attributed to alterations in BRCA1, a tumor-suppressor 
gene. Over 85% of alterations in the BRCA1 gene result in premature termination of the 
BRCA1 protein resulting in truncation. 
Using antibodies directed against the amino and carboxy terminal regions of the 
BRCA1 protein, immunohistochemical analysis was conducted on paraffin sections of 
paired ovarian cancer and normal tissue of ten patients. Mutation analysis, employing 
polymerase chain reaction (PCR) and single strand conformational polymorphism 
(SSCP) and gene sequencing, was also performed on DNA extracted from liquid 
nitrogen, snap frozen sections of paired malignant ovarian tissue and normal uninvolved 
tissue from the same ten patients. The tissue samples were selected from a high-risk 
population of women who were likely to carry a heritable BRCA1 gene alteration. 
Among the ten matched specimens, six tumor specimens revealed a reduction in 
BRCA1 C20 and D20 antibody reactivity. BRCA1 mutation analysis of these six tumors 
showed intragenetic loss of heterozygosity (LOH) at BRCA1 sites for all six specimens. 
From this group of six, two corresponding normal tissue specimens revealed decreased 
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BRCA1 C20 antibody reactivity. DNA analysis of the match normal tissue revealed a 
germline BRCA1 gene alteration in each of these two tissue specimens. No mutations 
were detected in the other four corresponding normal tissue specimens, and BRCA1 D20 
and C20 activities were normal. The remaining 4 paired samples showed no reduction in 
antibody reactivity, and no BRCA1 gene alterations were found in these ovarian tumors 
or their normal, uninvolved tissues. 
These results suggest that the degree of BRCA1 antibody reactivity correlates 
with BRCA1 gene alteration in both tumor and normal, uninvolved surgical specimens. 
An immunoreactivity assay for the BRCA1 amino and carboxy terminals may serve as a 
rapid and inexpensive assay for the detection of the presence of BRCA1 gene alterations 
in surgical specimens. 
2.2 Introduction 
Breast and ovarian cancers are among the most common diseases affecting 
women today. One out of eight women will develop breast cancer by the age of 85, and 
ovarian cancer is the leading cause of cancer deaths resulting from malignancies of the 
female reproductive system (1, 233). These cancers rank second and fourth, 
respectively, in terms of cancer mortality in American women, with greater than 200,000 
new cases reported each year (1). Five to 10% of these carcinomas are thought to result 
from a hereditary predisposition with germline mutations conferring autosomal dominant 
susceptibility (3). 
The mutation and subsequent inactivation of one gene, BRCA1, is believed to 
account for 45% of familial breast cancers and 80% of inherited breast and ovarian 
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cancer syndromes (2). These individuals have an estimated 84% life-long risk of 
contracting breast cancer and 44% risk for ovarian cancer (15,151). While BRCA1 
mutations have been implicated in the etiology of heritable breast and ovarian cancers, 
little or no conclusive role has been deduced for this gene relative to the sporadic forms 
of these diseases. Although 50% of ovarian cancers reportedly show loss of 
heterozygosity for BRCA1, low numbers of somatic mutations have been reported for 
BRCA1; 5 have been reported for sporadic ovarian carcinomas and none found in 
sporadic breast cancer (27, 28, 141). 
Etiological differences between heritable and sporadic forms of these cancers 
have suggested that phenotypic variations may also exist. Several studies have reported 
a large percentage of tumors from BRCA1 mutation carriers to be high-grade and of 
medullary or atypical medullary type (142-148). The preponderance of these high-grade 
tumors resulted in part from an increased rate of mitosis (142, 143, 148, 152). Also, 
estrogen and progesterone receptors are expressed less frequently within BRCA1 tumors 
(144-149). 
The pathology of breast cancers in predisposed women also differs from that of 
sporadic cases. Differences also exist between carriers of germline BRCA1 and BRCA2 
mutations. In general, BRCA 1-associated breast cancers have been reported as highly 
proliferating tumors (53). Correlation between mutation type and disease phenotype has 
been reported for another autosomal-dominant condition, neurofibromatosis type 2 
(106). In this study, symptoms were most severe when there was a truncation mutation. 
Ihe majority of heritable BRCA1 and BRCA2 mutations result in protein truncatioas 
within the coaserved terminal regioas of their respective proteins. 
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These have also been categorized as highly proliferative tumors (74, 82-85, 91, 
94). Within BRCA-mutation carriers, breast tumors removed from BRCA1 mutation 
carriers showed greater pleomorphism and higher mitotic count than similar tumors 
derived from carriers of a BRCA2 mutation (82-85, 91, 94). These findings suggest that 
breast cancers occuring in carriers or a BRCA1 mutation have a different natural history 
and possibly a different disease progression than carriers of a BRCA2 mutation or 
apparently sporadic cancers. Potentially, this difference would allow for the 
development of a reliable screening tool to detect heritable BRCA1 and BRCA2 
mutations based upon visual differences (34, 54). 
The multiple roles that BRCA1 and BRCA2 appear to play in DNA maintenance 
and repair make them important factors in maintaining genomic stability (155, 156, 166, 
167). Chromosome deletion of the wild type allele often results from genetic instability 
and is frequently precluded by a BRCA1 or BRCA2 germline mutation. The 
surrounding chromosome region also may be affected. This is detected with regional 
markers. Deletion of areas on the wild type allele such as this are referred to as loss of 
heterozygousity (LOH). When LOH occurs, expression of the wild type allele is lost. 
Therefore, LOH is detected by the loss or alteration of expression of 1 allele. 
Earlier, DNA analysis of breast tumors revealed LOH of the normal chromosome 
at certain genomic regions. These findings suggested that the areas were occupied by 
tumor suppressor genes (57, 154). Later, the designations BRCA1 and BRCA2 were 
assigned. Although BRCA1 plays a minor role in sporadic forms of breast and ovarian 
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cancer. LOH is frequently reported for the BRCA1 locus (12, 26-30, 41, 56, 57, 70, 118- 
121, 149, 150). In carriers of a BRCA1 or BRCA2 mutation, LOH is reported to occur 
in 88% of informative, or heterozygous, tumors (157-163). 
Since BRCA1 was first cloned and mapped to the long arm of chromosome 
17q21 (4), research efforts have focused on identifying genetic lesions and germline 
mutations within this gene, and their influence on genetic expression. Over 500 BRCA1 
alterations have been reported to date (38). Some of these include missense, ffameshifts 
and splice-site alterations. Some have been recurrent, others have been reported only 
once (5, 38). 
Recently, several studies have investigated the role of BRCA gene mutations in 
seemingly sporadic breast or ovarian cancer as well as the prevalence of BRCA 
mutations in specific populations. Individuals with no significant family history but with 
specific risk factors have been shown to be at increased risk of carrying a germline 
(heritable) BRCA gene mutation. The risk factors found to be significant include early 
age of onset of disease, bilateral disease, or Ashkenazi Jewish ancestry (15-25). In 
addition, while ovarian cancer is rarely the result of direct mutations of the ovary, loss of 
heterozygousity (LOH) of the BRCA1 gene has been detected in up to 50% of ovarian 
cancers (26-28). 
The complexity of the BRCA genes along with the paucity of common mutations 
has hindered the development of a simple assay for mutation detection. Both BRCA 
genes are large and produce very large proteins. Structurally, the BRCA1 gene contains 
24 exons and encodes a protein reportedly 190KDa to 240KDa. The normal functioning 
BRCA1 protein is unique. It contains few repetitive regions and has a very specific 
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amino acid sequence throughout including the amino-terminal and carboxy-terminal 
ends of the protein. While the actual size, location, and function of this protein have 
been the subjects of much debate, investigators have generally agreed that greater than 
85% of BRCA1 mutations are nucleotide insertions or deletions resulting in frameshift 
alterations and the consequent introduction of a premature stop codon (29,30). These 
lead to various truncation patterns of the BRCA1 protein. Therefore, most mutated 
BRCA1 protein products do not contain the normal, carboxy terminal amino acids. 
Current commercial and investigative methods for mutation analysis include 
sequencing of candidate polymorphisms detected by single strand conformation 
polymorphism (SSCP) analysis, clamped denaturing gel electrophoresis, or heteroduplex 
analysis. Also, direct DNA sequencing of the BRCA1 and/or BRCA2 genes, protein 
truncation test, and DNA chip technology are also used (29). These techniques are 
expensive to develop, labor intensive, and/or require substantial technical expertise. As 
a result, the cost of commercial testing is prohibitive. 
2.3 Hypothesis 
Since most BRCA1 mutations result in protein truncations, it was hypothesized 
that such mutations would be detected by immunohistochemical (IH) analysis by using 
commercially available antibodies directed against the BRCA1 amino and carboxy 
terminals. Specifically, it was postulated that antibodies directed against the amino- and 
carboxy-terminal amino acids would demonstrate a quantitative reduction in BRCA1 
carboxy-terminal reactivity in tissue carrying most BRCA1 mutations relative to their 
normal tissue. To test this hypothesis, we analyzed matched ovarian cancer tissue and 
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uninvolved tissue obtained from ten patients, at increased risk for heritable ovarian 
cancer. Ovarian cancer was studied, because greater than 50% of sporadic ovarian 
tumors are associated with BRCA1 gene alterations. The individuals’ normal tissue 
served as a control as such mutations are generally isolated to tumor only and thus not 
found in normal tissue. Individuals at increased risk for heritable ovarian cancer were 
selected, to potentially identify a subgroup of individuals with a heritable BRCA1 
mutation. These individuals possess BRCA1 alterations in involved and uninvolved 
tissue. These tissue specimens would help determine whether immunoreactivity of the 
BRCA1 protein could predict the presence of germline mutations within normal 
uninvolved tissue. 
2.4 Objectives 
The objectives of this study were to: 
1. Collect surgical specimens of tumors and matched uninvolved tissue from high-risk 
ovarian cancer patients. 
2. Determine whether germline BRCA1 mutations could be detected in normal 
uninvolved tissue, using immunohistochemical analysis of the amino and carboxy 
terminals of the BRCA1 protein. 
2.5 Materials and Methods 
Frozen and parraffm embedded, matched ovarian cancer tissue and uninvolved, 
normal tissue from individuals with early age of onset (<45 years old) were obtained 
through the Gynecological Oncology Group/Cooperative Human Tissue Network 
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ovarian tissue bank (Columbus, OH). Primary site cancers not previously treated with 
chemotherapy or radiation were used. Patients with early age onset of ovarian cancer 
were chosen to increase the probability of receiving samples from patients with heritable 
BRCA1 mutations. Ten experimental samples were chosen from an original group of 
thirty-eight pairs supplied by the GOG tissue bank. Selection of these ten samples was 
based upon BRCA1 expression in their normal uninvolved tissue. Many normal tissue 
samples were comprised primarily of fatty tissue that did not express BRCA1 protein. 
These were not used. 
Genomic DNA was extracted from frozen tissue and tumors using a Puregene 
DNA Isolation Kit (Gentra Systems, Inc.). Briefly, cells were lysed using an anionic 
detergent while limiting enzyme activity to preserve DNA. RNA was enzymatically 
digested and salt precipitation was utilized to remove protein contaminants. Genomic 
DNA was then isolated by alcohol precipitation and resuspended in a buffered solution. 
Optical density readings were done on all DNA extractions at A26o and A2so to determine 
DNA quantity and purity. 
For single stranded conformational polymorphism (SSCP) analysis, polymerized 
chain reaction (PCR) amplification using genomic DNA was performed with intron- 
based primers surrounding each of 22 BRCA1 exons. Four overlapping primer sets were 
used to examine exon 11. Exons 6 and 7 were amplified as one product (7). BRCA1 
primers were synthesized by Midland Reagent Company (Midland, TX). PCR was 
carried out in a volume of 50 ul containing lug genomic DNA, 10 mM Tris-HCl (pH 
8.3), 1.5 mM MgCl2, 50 mM KC1, 200 uM concentration of each dATP, dTTP and 
dGTP, 20 uM dCTP, 1 uCi of labeled [32P] dCTP (6000 Ci/mmol; Amersham, Chic., IL). 
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Each primer was 1.0 uM and 0.4 units of Amplitaq Polymerase (Perkin Elmer 
Cetus, CT) was used in each reaction. DNA amplification was done using a Perkin 
Elmer Cetus 9600 thermal cycler. A 46 cycle 3-temperature cycling program was used 
to generate PCR product. The program initiates with 1 minute at 95C. Cycles 
commence with 10 sec. at 95C, 10 sec. at 68C, 10 sec at 72C. This was repeated for 4 
sets of 4 cycles with 68C descending to 60C in 2C increments every 4 cycles. When 
60C was reached, 30 cycles were repeated followed by a single 5 min. at 72C (7). 
A modification of an SSCP protocol described by Epstein et al. (232) was used 
for detecting BRCA1 gene alterations. A 1 ul aliquot of the PCR product was diluted 
into 9 ul of denaturing-loading buffer consisting of 95% formamide, 10 mM NaOH, 
0.05% xylene cyanol FF and 0.05% bromophenol blue, by volume. The 10 ul mixture 
was heated to 95C for 10 min. and plunged into an ice bath for rapid cooling. A 3 ul 
aliquot of this solution was then transferred to a 5% polyacrylamide/bis gel containing 
5% glycerol and 0.5X Tris-borate EDTA for electrophoresis. Gels were prerun at 30 
watts for 30 min. before loading samples. Upper and lower reservoirs of the gel 
apparatus contained 0.5X Tris-borate EDTA buffer. Gels were run at room temperature 
for 130 watt hours after which they were transferred to 3mm chromotography paper, 
placed in plastic wrap and exposed to reflection autoradiography film (Biomax MR film, 
Kodak) for 18 to 24 hours at -70C. Each gel contained PCR product, from a given 
primer set, for each individual’s uninvolved tissue and corresponding tumor specimen. 
SSCP gels were scored for unique banding patterns and lost bands. Since the PCR 
product contained exon and part of the adjacent intronic sequence where variations, 
unique bands seen in uninvolved tissues, were scored as polymorphisms. 
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As new mutations in ovarian tumors are rare and LOH is common, LOH was 
inferred when unique SSCP bands were noted to be absent in the tumor specimens 
relative to their corresponding uninvolved normal tissue. 
Genomic DNA sequencing was completed using the Amplicycle Sequencing Kit 
(Perkin Elmer Cetus, CA). This is a modified version of the Sanger method (232) for 
sequencing double stranded DNA (dsDNA) and does not require subcloning and/or 
extensive purification prior to sequencing. Sequencing utilized 33P isotope and was 
conducted according to the protocol supplied by Perkin Elmer Cetus. Both alleles were 
sequenced for each polymorphism identified by SSCP analysis. Reaction cycling was 
done in a GeneAmp PCR System 9600 (Perkin Elmer Cetus, CA). Termination reaction 
cycling conditions used an initial step of 1 min. at 95C followed by 25 cycles of a 3- 
temperature cycling protocol; 30 sec. at 95C, 30 sec. at 68C and 1 min. at 72C. 
Reactions were then arrested by the addition of 4 ul stop solution (the same composition 
as that used for SSCP). Sequencing gels consisted of 6 to 8% acrylamide/bis solution, 
IX Tris-borate EDTA and 7M urea. Gel solution was passed through a microfilter prior 
to use, and all gel glass plates were silonized on one side. Gels were prerun for 30 min. 
with IX Tris-borate EDTA buffer at 60-75 watts. Just prior to use, sequencing reactions 
were denatured by heating to 90-94C for 3 min. A 3 ul sample of the denatured 
sequence solution was dispensed from each sequence reaction and loaded onto the gel. 
Gels were run for 2-3 hours at 60-75 watts, cooled, then fixed in a 10% acetic 
acid, 10% methanol solution, by volume, for 30 min. to remove urea, and then was 
transferred to 3 mm chromotography paper. 
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Excess liquid was drained from the gel surface when removed from the solution 
to allow for easier transfer. Gels were covered with plastic wrap, backed with a second 
sheet of 3 mm chromatography paper and dried in a gel dryer model 583 (Bio-Rad 
Laboratories). Sequence ladders were resolved by autoradiographs through direct 
contact of dried gels to Biomax MR x-ray film (Kodak, Inc. Rochester, NY). Exposure 
time was 24-48 hours at room temperature. 
To evaluate each sample utilizing immunohistochemistry, a minimum of two 
slide-mounted, paraffin-embedded tissue sections were obtained for each tissue sample 
analyzed for BRCA1 mutations. Three 5 min. xylene baths followed by hydration in a 
descending concentrations of alcohol dip (100%, 95%, 70% and water) was used initially 
to deparaffinize each sample. Slide mounted tissue sections were then placed in a 0.01 M 
citrate buffer (pH 6.0) and microwaved for 10 min. at low power followed by a 
deionized, distilled-water rinse and a 30 min. treatment in 1% H2O2. Tissue was then 
washed in lOmM phosphate buffer saline solution (PBS) and treated for 20 min. with 
blocking solution antigen (BSA) (1% BSA/PBS , 3 drops goat serum). Excess blocking 
solution was removed and one of the two primary antibodies was applied. 
Antibody-treated sections were incubated at room temperature for one hour. The 
two primary antibodies used were C-20 and D-20 (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA). Each are affinity-purified, rabbit, polyclonal antibodies raised against a 
peptide corresponding to the amino acid sequence at opposite ends of the BRCA1 
protein. The C-20 antibody corresponded to the carboxy terminus of the BRCA1 protein 
and the D-20 corresponded to the amino terminus. A biotinylated, affinity-purified, anti¬ 
immunoglobulin supplied in the Vectastain ABC Kit (Vector Laboratories, Inc.) was 
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applied as a secondary antibody. Both primary and secondary antibodies were diluted 
with PBS to a range of 0.5-1.0 ug/ml and 5-10 ug/ml, respectively. Elucidation of 
antibody binding was realized with the precipitation-producing chromogen di- 
aminobenzidine tetrahydrochloride (DAB) followed by hematoxylin counterstaining or 
3-amino-9-ethylcarbazole (AEC) with an eosin counterstain according to the 
manufacturers’ supplied protocols. Coverslips were applied to treated tissue samples for 
microscopic viewing. The appearance of antibody staining on each treated tissue section 
was evaluated visually three times using an optical microscope. Staining intensity, 
indicative of antibody reactivity, was noted for each slide as either normal or reduced. 
2.6 Results 
Among the ten paired specimens analyzed, no change in immunohistochemical 
reactivity was detected in four tumors or their related, uninvolved tissues (Table 1. 
Figure 2). Mutation analysis employing SSCP revealed no BRCA1 gene alterations 
present in any of these four pairs of samples (Table 1). The six remaining pairs 
displayed reduced immunohistochemical reactivity of D20 and C20 in only tumor tissue 
(Table 1, Figure 2). DNA mutation analysis for these tumor specimens, using SSCP, 
showed a reduction in bands for many exons of the BRCA1 gene relative to their 
uninvolved normal tissue. This was interpreted as allelic loss of multiple intragenetic 
areas within the BRCA1 gene for each of these tumors. This is consistent with the high 
occurrence of LOH reported for ovarian tumors. The remaining four normal tissue 
samples were immunohistochemically normal. 
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Two uninvolved normal tissue samples associated with this group showed a reduction in 
C20 antibody (Table 1, Figure 2). No BRCA1 gene alterations were detected in this 
latter group of four. However, a germline BRCA1 mutation was detected in each of the 
two former normal tissue samples that expressed reduced C20 antibody reactivity (Table 
2, Figure 2). Germline BRCA1 mutations found in these two normal uninvolved tissue 
samples were characterized as insertions. Both mutations produced a truncated BRCA1 
protein (Table 3). 
The sensitivity (number testing positive/true positives X 100) and specificity 
(number testing negative/true negatives X 100) of this immunohistochemical method for 
detection of BRCA1 mutation were each 100%. The positive predictive value (true 
positives/ those testing positive X 100) of this method was 100% and the negative 
predictive value (true negatives/ those testing negative X 100) was 100%. 
TABLE 1 
BRCA1 Immunohistochemical Analysis BRCA1 Mutation Analysis 
Number Tumor Tissue Uninvolved Tissue Tumor Tissue Uninvolved Tissue 
Of Samnles D20 C20 D20 C20 
4 normal normal normal normal no mutations detected 
4 l l normal normal LOH none detected 
2 J. i normal J. LOH germline mutation 
Table 1. BRCA1 Immunohistochemical analysis and mutation analysis of surgical 
specimens of ten paired samples of ovarian tumors and normal, uninvolved tissues. 
■ = reduced antibody reactivity. LOH = loss of heterozygosity. 
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Sample 
TABLE 2 
BRCA1 SSCP Mutation Analysis- aberrant band locations 
Ovarian tumor Paired normal tissue 
A 9,11c. 1 Id. 13.17.18. 20 none 
B 9. 11c. lid. 15.22.24 none 
C 2.4. 11a. lib. 15.18.22.24 none 
D 7,11c. lid. 13.15.16 none 
E 12.13,15.21.22.24 p 
F 13,15. 17. 18.22.24 15 
Table 2. BRCA1 SSCP mutation analysis of 6 paired surgical specimens of matched 
ovarian tumors and normal uninvohed tissues. A-F. Exons are identified where 
reductions in allelic bands for the BRCA1 gene were revealed for six ovarian tumors 
and location of two germline BRCA1 mutations in paired normal tissue. 
Characterization of 2 Germline BRCA1 Mutations 
Identified In Surgical Specimens of Normal Tissue 
Exon 12 - "g~ insen at nucleotide site 4167. Frameshift starts at 
codon 1389Resulting in GTA to TAA i stop) at exon 12 13 splice site. 
Expected sequence: C AG AGT GAC ATT 
Actual sequence: CAG AGT GAG CAT 
Exon 15 - Two ~c~ insertions at nucleotide sites 54325 and 54328. 
Frameshift starts ai codon 1532 resulting in TGA (stop) at codon 1548. 
Expected sequence: GAT GTG GAG 
Actual sequence: GAC TGT CGG 
Table 3. Characterization of tw o germline BRCA1 mutations identified in 
surgical specimens of normal tissue. Tissue samples were from paired surgical 
specimens of ovarian tumors and uninvoh ed normal tissues selected from a 
population at high-risk for earning a germline BRCA1 mutation 
2.7 Discussion 
BRCA1 gene mutations are associated with approximately half of all ovarian 
cancers, with BRCA1 germline alterations representing five to ten percent of this 
population This analysis of ten high-risk ovarian cancer patients was consistent with 
these findings. Six of ten malignancies examined could be attributed to BRCA1 gene 
mutations and two paired samples were found to contain BRCA1 germline mutations. 
Loss of intragenetic sequences of the BRCA1 gene, determined by a reduction in the 
SSCP banding patterns, was found in six of these tumor specimens. LOH of areas in 
and around the BRCA1 gene reportedly occurs with great frequency (12, 26-30, 118- 
121, 149, 150, 161-163). This is particularly true throughout chromosome 17 in ovarian 
carcinomas. 
Although the biological significance of this occurrence has yet to be determined, 
identification of areas that harbor tumor-suppressor genes have been identified by the 
presence of LOH using restriction-fragment-length-polymorphism analysis (57, 154) 
In this study, antibodies were used to detect specific regions of the BRCA1 
protein. Earlier, the use of different antibodies and techniques resulted in conflicting 
results reported by some research groups (40, 45, 48, 49). There has been some 
resolution to the debate centered on the subcellular location of the BRCA1 protein in 
tumor and normal breast cells alike. Smaller BRCA1 protein products have been found, 
along with their mRNA splice variants, in different cell types (18, 44). Additionally, 
there is evidence for a nuclear localization signal in normal BRCA1 protein. Protein- 
protein interactions may also be required for translocation of the BRCA1 protein to the 
nucleus (40). Certain domains of the BRCA1 protein are key sites of biological activity 
and are found in all splice variations. Two of these are the amino terminal zinc finger 
region and the carboxy end. These findings have allowed a better understanding of how 
specific site mutations may lead to variations in subcellular location of BRCA1 protein 
and also help explain conflicting results. 
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One fact that is not in contention, however, is that approximately 90% of all BRCA1 
mutations lead to alterations resulting in the introduction of a premature stop codon (6). 
The product is a truncated BRCA1 protein that does not contain the carboxy terminal. 
The goals of the present study were to determine whether immunohistochemistry 
could serve as a tool for detecting LOH of the BRCA1 gene in surgical specimens of 
ovarian tumors and similarly, for detecting germline mutations, which result in BRCA1 
protein truncations, in normal surgical specimens. 
In this study immunohistochemical interpretations strongly correlated with the 
presence or absence of BRCA1 gene mutations. The high sensitivity, specificity, and 
positive and negative predictive values observed suggest that immunohistochemistry 
may serve as a useful tool in the detection of BRCA1 gene alterations and mutations in 
frozen surgical specimens. Additionally, immunohistochemistry is significantly less 
expensive and less labor intensive than current DNA analysis further adding to its utility. 
BRCA1 immunohistochemical characterization may also prove useful in enhancing 
our understanding of the pathogenesis of ovarian cancer. This method may prove 
valuable in the molecular characterization and grading of ovarian tumors and aid in the 
development and administration of more specific therapies. This method may also aid in 
the rapid and inexpensive detection of germline mutations in normal surgical specimens. 
This may be particularly important for families wishing to determine their risks of 
heritable breast/ovarian cancer, in which the only informative, biologic source for gene 
characterization is archival tissue of affected, deceased relatives. 
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Above, Tumor Specimens Above, Normal Uninvolved Tissue 
Figure 2. Surgical specimens of paired ovarian tumor and normal uninvolved 
tissue. Slide mounted, thin sections. Samples stained with a BRCA1 antibody, 
D20 amino antibody or C20 carboxy antibody. Antibody expression indicated 
by red-brown color. Top row,normal expression. Middle row, reduced D20 
and C20 expression in tumor tissue only. Bottom row, reduced D20 and C20 
expression in tumor, reduced C20 in normal tissue. 
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CHAPTER 3 
IMMUNOHISTOCHEMICAL ANALYSIS OF BRCA2 EXPRESSION IN 
HUMAN BUCCAL CELLS 
3.1 Overview 
Cytospin deposited human buccal cells were studied for BRCA2 expression. 
Protein expression was detected with two goat polyclonal antibodies (Santa Cruz 
Biotechnology, Inc), 1-17 to the amino terminal and C-15 to the carboxy terminal of 
human BRCA2. Both antibodies distributed to the nuclear and cytoplasmic compartment 
of the cells. Greatest reactivity was seen in the cell nucleus. Approximately 30% - 40% 
of cells displayed positive antibody reactivity. Earlier, buccal cells were assayed with 
BRCA1 antibody. Approximately 85% - 90% of cells showed positive reactivity. RT- 
PCR studies of human buccal cell mRNA demonstrated levels of BRCA2 gene 
transcription consistent with our immunohistochemical findings. We conclude that 
buccal cells may be used as a minimally invasive, normal cell source for which to 
conduct immunohistochemical analysis of the BRCA2 protein. 
3.2 Introduction 
Some 20,000 women diagnosed annually with breast or ovarian cancer are 
thought to have been genetically predisposed to contracting this disease (1-4). 
Collectively, BRCA1 and BRCA2 account for approximately 90% of heritable breast 
and ovarian cancers and for an estimated 1 in 400 sporadic forms of these cancers that 
result from somatic mutations in the population at large (1-4). Carriers of a germline 
mutation in the BRCA1 or BRCA2 gene are placed at a highly penetrant, autosomal 
dominant predisposition to contracting cancer. 
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These genetic lesions confer an 85% lifetime risk of contracting breast cancer, 
whereas 12.5% is the normal rate of occurrence in the general population (1-4). 
Mutations in each of these genes confer different levels of susceptibility to 
various types of cancer. BRCA1 mutations are found in high frequency in families with 
both breast and ovarian cancer and relatively low frequency in site-specific breast 
cancers, while a 3 and 4-fold increased risk is reported for prostate and colon cancers 
respectively (3, 5). BRCA2 mutations are found in highest frequency in female breast 
cancer and lower frequency in ovarian cancers. BRCA2 has also been associated with 
male breast, prostate and laryngeal cancers as well (3). 
Using antibodies raised against specific gene products has provided much 
information about conditions and kinetics of the induction of gene expression. Such is 
the case with the BRCA2 gene. Immunohistochemical analysis has allowed localization 
of the BRCA2 protein to subcellular regions and has aided in the elucidation of critical 
regions of protein interactions. This information has provided clues to the biological 
functions of the BRCA2 protein and helped detail regulatory pathways and define the 
overall functional roles for this tumor suppressor gene. 
Similar to BRCA1, BRCA2 has clearly been shown to be cell cycle regulated 
with induction occurring in late G1 early S phase of the cell cycle (77, 79-83). Patterns 
of RNA expression for both BRCA1 and BRCA2 were similar during the proliferation 
phase of the cell cycle while transcripts from each gene were not detected in quiescent 
cells. 
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One critical area identified on the BRCA2 protein is the active binding site 
located at the amino terminal on exon 3. This site shows transcriptional activation 
potential with BRCA2 residues 290-453 interacting with a transcriptional co-activator 
protein, P/CAF (123). The N-terminal region of the BRCA2 protein also appears to have 
the capacity to activate transcription. Although this regional role is not clearly defined, 
amino acid segments within this region of BRCA2 are similar to the JNK-docking site 
found in the JUN protein. This JNK-docking site reportedly plays a regulatory role in 
transcription activation (124). 
Interaction between the BRCA2 protein and RAD51 clearly suggests BRCA2 is 
also a component of the DNA damage response pathway (88, 125, 126). This is based 
on earlier findings reported for the product of another tumor suppressor gene, the p53 
protein, and the RAD51 protein. These are two well-known components of the DNA 
damage response pathway (130, 131). BRCA2 interacts directly with RAD51 through 
two binding sites. One site is located in the N-terminal region encoded by exon 11. The 
second, the c-terminal region of the BRCA2 protein (88, 86, 109, 114). Recently, a 460- 
Kda nuclear BRCA2 phosphoprotein was reported to form in vivo complexes with both 
p53 and RAD51. Also, exogenous BRCA2 expression in cancer cells inhibited 
transcriptional activity of p53. RAD51 coexpression reportedly enhanced the inhibitory 
effect (127). The importance of the BRCA2 protein’s COOH terminus (amino acids 
3140-3328) to RAD51 mediated DNA repair was shown by analysis of cultured cells 
with a deletion of this region. Cells of this type were hypersensitive to gamma-radiation 
but were not sensitive to UV light. These cells also maintained the G1 -S and G2-M 
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checkpoints after exposure. This suggests defective recombination repair while 
nucleotide excision repair remained intact. Cell cycle for COOH-deleted cells was 
maintained at a similar rate as wild type cells. 
However, these mutated cells underwent senescence more rapidly. This data 
supports the hypothesis that deletion of BRCA2 allows for cancer development by 
defective RAD51 -mediated DNA repair and not by defective cell cycle regulation (86, 
112, 128, 129). 
BRCA2 expression has been reported in testis using multiple tissue northern 
(MTN) filters probed with PCR product. Also, RT-PCR analysis showed that BRCA2 
transcription occurs in brain, breast, kidney, lung, leukocytes, ovary, pancreas, prostate, 
spleen, stomach and thymus (14). The BRCA2 protein has also been shown to undergo 
differential splicing, giving rise to a novel variant protein called BRCA2a. This splice 
variant lacks a putative transcriptional activation domain. Levels of expression for both 
BRCA2 and BRCA2a protein are differentially expressed. High expression for both 
splice variants is found in the thymus and testis and low to moderate expression is found 
in mammary gland and prostate. Varying levels of expression of these splice variants 
have been interpreted to indicate that each has a role in the development and 
differentiation of cells comprising these tissues (122). 
Previously, we demonstrated that BRCA1 protein was expressed in normal 
human cells, which were obtained by a minimally invasive method, from the oral buccal 
cavity (233). BRCA1 protein reactivity was detected by immunohistochemistry with 
three commercially available antibodies, D20 (Santa Cruz Biotechnology), MSI 10 and 
MS 13 (Oncogene). Distribution of BRCA1 protein was both cytoplasmic and nuclear, 
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and was present in about 80% of buccal cells. These cells provide a healthy, easily 
accessible model system in which to study intracellular mechanisms of BRCA1 protein 
action. 
3.3 Hypothesis 
Buccal cells are a rapidly proliferating epithelial cell population that would be 
expected to contain randomly cycling cells, both positive and negative, for expression of 
the BRCA1 and BRCA2 protein. This was observed for the BRCA1 protein. Given the 
many similarities between expression of the BRCA1 and BRCA2 protein, the hypothesis 
of this study is that human buccal cells will transcribe the BRCA2 gene and express the 
BRCA2 protein. 
3.4 Objective 
The present study sought to determine whether BRCA2 transcription occurs 
within human buccal cells and whether the BRCA2 protein expression can be detected in 
this cell source. To accomplish this, total mRNA was extracted from a sample of human 
buccal cells and RT-PCR (reverse transcription-polymerase chain reaction) performed 
for the BRCA2 gene. Protein expression of the BRCA2 protein was examined with 
antibodies directed at the BRCA2 amino and carboxy terminals. 
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3.5 Materials and Methods 
3.5.1 RT-PCR analysis. 
Total buccal cell RNA was extracted with RNAgents, Total RNA Isolation 
System Kit Z5110 (Promega, Madison, WI). Pelleted buccal cells from a fresh pooled 
sample were treated with 1 ml pre-chilled denaturing solution (25 g guanidine 
thiocyanate in 33 ml citrate/sarcosine/b-mercapthoethanol, CBS buffer) for 5 minutes. 
Cells were lysed by aspiration with a sterile Pasteur pipette, and 800 ul of 2 M sodium 
acetate was then added. Reverse transcription was carried out with a GeneAmp RNA 
PCR Kit N808-0017 (Perkin Elmer Cetus, Foster City, CA) following the protocol 
supplied by the manufacture. Thereafter, each cDNA sample was amplified for 20 
cycles using BRCA2 primers B2#F9833 (5’- CGTACACTGCTCAAATCATTC) and 
B2#R10061 (5’- GACTAACAGGTGGAGGTAAAG) (4). Samples were then diluted 
10-fold and a BRCA 2 cDNA amplicon spanning the last splice junction was amplified 
using 5 ul aliquots (4). Thirty cycles were completed using primers B2#F9857 (5’- 
GTACAGGAAACAAGCTTCTGA) and B2#R10061 once again. Primers were 
synthesized by Midland Certified Reagent Co., Midland, TX. Initial PCR conditions 
were: a single denaturing step of 95 C (1 min); 20 cycles of 96 C (6 sec), 55 C (15 sec), 
72 C (1 min). Secondary PCR-amplification conditions differed only by an increase in 
the number of cycles that were used. Primer sequences and PCR amplification 
conditions were described in Tavtigian et al. (4). Final PCR product was excised from a 
1% agarose gel to remove extraneous primary product. Product was cleaned and 
concentrated with Qia quick PCR Purification Kit 28104 (Qiagen, Santa Clarita, CA) for 
better visualization, followed by gel electrophoresis in 1% agarose, 0.5X TBE buffer. 
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PCR product was visualized by ethidium bromide reaction over a UV light source. 
Controls were: RT positive control-pAW109 (308bp), RT negative control-no reverse 
transcriptase added, RT and PCR negative controls-water, and PCR positive control-cord 
blood DNA used. All controls were carried through PCR amplification. 
Cloned DNA sizes were estimated relative to their migration against a 123 bp 
ladder (Gibco, BRL, Gaithersburg, MD). 
3.5.2 Buccal cell immunohistochemistry: 
Buccal cells were collected from the oral cavity of normal male and female adult 
donors with cotton swabs moistened with water. Donors were in good health and had no 
personal or family history of cancer. Buccal cells were obtained by having the test 
subject vigorously rub the inner cheek with a cotton swab, moistened with sterile water, 
for approximately 20 seconds on each side. The cotton swab was then submerged in 500 
ul of PBS, phosphate buffered saline (PBS: pH 7.5, 0.9% saline, 0.1% crystalline grade 
bovine serum albumin) contained in a glass vial and the cells were resuspended by gentle 
agitation. Cells from 6 individuals were pooled and counted using a hemocytometer 
(Fisher Scientific Co., Pittsburg, PA). The pooled buccal cell sample was diluted to a 
final concentration of 32,000 cells/ml PBS. One-half milliliter of buccal cell solution 
was cytospin deposited upon Superfrost (Fisher Scientific Co., Pittsburg, PA) precleaned 
microscope slides using a programmable cytospin (Shandon Inc., Lemer Laboratories, 
Pittsburg, PA) centrifuge. Cells were fixed in a 50:50 acetone:methanol solution, at - 
20^C for seven minutes. Air-dried slides were stored at -70^C in sealed boxes. Prior to 
immunoassay, slides were rinsed twice for 15 minutes in PBS using a mechanical rotator 
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for agitation. The rinsed slides were transferred to slide trays having humidified 
chamber-type holders that allow the slides to lie flat so reagents may be deposited onto 
the region of each slide containing the cells. Excess PBS was removed from each slide 
using a suction pipette. Excess blocking solution was also removed and one of the two 
primary antibodies to the human BRCA2 protein was applied. 
Primary antibodies used were two goat polyclonal antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA); 1-17 to the amino terminal and C-15 to an epitope 
located at the carboxy terminal end. No antibody cross reactivity occurs with the 
BRCA1 protein. Antibody dilutions and immunoperoxidase assay conditions were as 
provided by the supplier. Incubation of antibody-treated sections was modified to one 
hour at room temperature followed by overnight incubation at 4 C. A biotinylated, 
affinity-purified, anti-immunoglobulin labeled antibody supplied in the Vectastain ABC 
Kit (Vector Laboratories, Inc.) was applied as a secondary antibody which binds to the 
primary antibody. Both primary and secondary antibodies were diluted with PBS to a 
range of 0.5-1 .Oug/ml and 5-10ug/ml, respectively. Elucidation of antibody binding was 
realized with the precipitation-producing chromogen di-aminobenzidine 
tetrahydrochloride (DAB) followed by hematoxylin counterstaining to display all nuclei 
present. This produced brow regions of antibody binding. An alternate precipitant, 3- 
amino-9-ethylcarbazole (AEC), producing blue/black regions of antibody deposition, 
was used on some samples followed with an eosin counterstain according to the 
manufacturers’ supplied protocols. Coverslips were applied to treated tissue samples for 
microscopic viewing. 
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Negative control for the BRCA2 polyclonal goat antibodies was preincubation 
with excess immunizing peptide obtained from the supplier of the BRCA2 antibodies. 
Two additional negative controls were also used. These were substitution of goat IgA 
for primary antibody and secondary antibody applied without the application of a 
primary antibody. Positive controls were A431 cells, human epidermoid carcinoma 
(American Type Culture Collection, Manassas, VA). 
3.6 Results 
Polymerase chain reaction of reverse transcribed buccal cell RNA and fetal cord 
blood DNA produced BRCA2 cDNA products of expected size; approximately 210bp 
(Figure 3). Antibody reactivity was positive for the BRCA2 protein in 30% - 40% of 
cytospin deposited human buccal cells, for the two antibodies, C-15 and 1-17, used here 
(Figure 4). These results were consistent in all samples. Cellular distribution of 
immunoreactivity for each BRCA2 antibody was seen in the nucleus and cytoplasm 
(Figure 4). Reaction intensity, determined by lighter or darker coloration, was greatest in 
the nucleus of most buccal cells. 
3.7 Discussion 
The BRCA 2 gene is transcribed and the BRCA 2 protein is expressed in normal, 
human buccal cells. Detection of the BRCA2 protein in buccal cells can be made with 
antibodies directed against the protein’s amino and carboxy terminals. A mixed 
population of buccal cell expressing positive or negative reactivity to BRCA2 
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antibodies was also seen with BRCA1 antibodies. These results are concordant with 
reports stating that both these proteins are expressed in a cell cycle manner (77, 79-83). 
While the localization between nuclear and/or cytoplasmic distribution of BRCA1 
protein remains questionable, current results for BRCA2 suggest that this protein resides 
in the nucleus. Our immunohistochemical analysis in human buccal cells showed 
BRCA2 localized strongly to the nucleus. However, antibody reactivity for the BRCA2 
protein was also found within the cytoplasm. 
Additionally, intracellular distribution patterns using antibodies D20 and C20 for 
BRCA1, and 117 and Cl5 for BRCA2, were very similar. While protein activation or 
functions may occur at one or more intracellular sites, protein synthesis occurs on the 
ribosomes within the cytoplasm. It is therefore reasonable to assume that detection for 
both may also be realized within the cytoplasm, prior to transport of the protein to the 
cell nucleus. 
Reverse transcriptase-PCR for BRCA2 mRNA in human tissue was reported 
previously by Tavtigian et al. (4). That study demonstrated BRCA2 mRNA in brain, 
breast, kidney, lung, leukocytes, ovary, pancreas, prostate, testes, spleen, stomach and 
thymus. In our study, performing RT-PCR for BRCA2 in human buccal cells was 
technically challenging. Tiered PCR amplifications and concentration of the end cDNA 
product was necessary for detection of BRCA2-PCR product without the use of 
radioactive labeling. Reverse transcriptase PCR for BRCA1 in human buccal cells was 
not as formidable a task. BRCA1 and BRCA2 mRNA expressions are differentially 
regulated by sex hormones. Additionally, antibody expression for the BRCA1 protein 
was found in a larger percentage of buccal cells than was BRCA2; 60% vs 40% 
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Among possible explanations for low amplification of BRCA2 cDNA are: 1. a low 
reserve pool of mRNA, suggesting a different type of functional gene regulation for the 
BRCA2 than the BRCA1 gene; 2. the presence of several pools of BRCA2 mRNA in 
buccal cells representing various splice variants of this large protein, with primers able to 
select for only part of the total; 3. inefficient attachment of the primers to cell BRCA2 
mRNA and/or less than optimal PCR conditions. Further studies are required to 
determine which, if any, of the above explanations are valid. 
We conclude buccal cells may prove to be a minimally invasive cell source with 
which to study BRCA2 protein expression and functions. 
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Figure 3. BRCA2 cDNA product from 
RT-PCR performed on total RNA 
extracted from normal human 
buccal cells. Lane 1, RT-PCR 
negative control-no reverse transcriptase 
added. Lane 2, BRCA2 PCR negative 
control,water used. Lane 3, BRCA2 PCR 
positive control-cord blood DNA used. 
Lanes 4 and 5, BRCA2 RT-PCR from RNA 
isolated from human buccal cells. 
Lane 6, RT-PCR positive control- 
pAW 109 (308bp) used. Lane 7, 
123bp ladder. Lane 8, empty. 
Figure 4. Immunohistochemical 
analysis of BRCA2 protein in 
normal human buccal cells. 
1-17 amino terminal antibody. 
Top picture. C-15 carboxy 
terminal antibody 
bottom picture. BRCA2 Protein 
antibody reactivity indicated 
by red-brown color 
CHAPTER 4 
A MINIMALLY INVASIVE ANTIBODY-BASED ASSAY DETECTS BRCAI 
AND BRCA2 PROTEIN TRUNCATIONS INDICATIVE OF THE PRESENCE 
OF GERMLINE MUTATIONS 
4.1 Overview 
Mutations in BRCAI and BRCA2 reportedly account for 90% of predisposed 
women diagnosed with breast or ovarian cancer each year. Approximately 4% of 
women of reproductive age have a significant family history. Still other mutation 
carriers reportedly lack a significant family history of cancer and erroneously believe 
they are low risk. 
Currently, clinical genetic testing employs gene sequencing. This technique, 
when used clinically, is expensive and time consuming. Earlier, we reported on 
developing an antibody-based assay that correlated with BRCAI germline alterations in 
surgical specimeas from individuals with ovarian cancer. Subsequently, buccal cells 
were analyzed for their utility as a minimally invasive cell source for this assay. Results 
of RT-PCR showed that the BRCAI and BRCA2 genes are traascribed in buccal cells. 
Protein expression was confirmed for each gene using immunohistochemical techniques. 
Here we present the results of a double blind study of 13 highly selected, at risk 
individuals. Mutation analysis and/or direct sequencing were conducted on BRCAI 
and/or BRCA2 for each individual. Buccal cells were also collected from each patient 
and were ased to conduct an antibody-based assay in which the amino and car boxy 
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terminals of the BRCA1 and BRCA2 proteins were detected. In 12 of these cases, the 
antibody-based assay correctly predicted the presence or absence of a BRCA1 or 
BRCA2 germline mutation. For the remaining individual, the immunohistochemical 
analysis did not correlate with sequencing results and may be a false positive. The 
negative predictive value of this assay was 100%. The positive predictive value was 
approximately 90%. These results suggest that a simple, antibody-based assay, may 
serve as a rapid, minimally invasive and inexpensive clinical tool for screening 
individuals for BRCA1 and BRCA2 mutations that result in protein truncations. 
4.2 Introduction 
Heritable BRCA1 and BRCA2 mutations are reported to collectively account for 
90% of predisposed women diagnosed with breast or ovarian cancer (1-4). Germline 
mutations in the BRCA1 or BRCA2 gene place these individuals at high risk of 
contracting various cancers. These genetic lesions confer up to an 85% lifetime risk of 
contracting breast cancer, whereas the normal risk of occurrence is estimated at 12.5% in 
the general population (1-4). 
For both of these two genes a mutation confers different levels of susceptibility to 
breast and to ovarian cancer, as well as to some other types of cancer. BRCA1 mutations 
are found in high frequency in families where both breast and ovarian cancer has 
occurred, and relatively low frequency in site-specific breast cancers. Also, a mutation 
to this gene reportedly increases risk for prostate and colon cancers 3 and 4-fold, 
respectively (3, 5). 
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In contrast to BRCA1, BRCA2 mutations are found in highest frequency in 
female breast cancer and in lower frequency in ovarian cancers. BRCA2 alterations are 
also associated with male breast cancer and other site-specific cancers (3, 10). Recently, 
DNA analysis was conducted on 112 families. Each family contained a minimum of 2 
cases of epithelial ovarian cancer. All cancer cases were accounted for by mutations in 
these two genes. Additionally, germline mutations were four times more common in the 
BRCA1 gene than BRCA2. No evidence for other susceptibility genes was found, 
leaving a high probability that BRCA1 and BRCA2 mutations may be responsible for all 
familial ovarian cancer (168). 
Some ethnic populations contain high frequencies of specific mutations in 
BRCA1 and BRCA2 (6). However, the vast majority of mutations reported to date are 
distributed over their whole coding sequences. In BRCA1, over 500 mutations have 
been identified. This list includes missense mutations, frameshifts, splice-site alterations 
insertions and large deletions (2, 7, 11-14, 38). In BRCA2, however, the majority of 
mutations described involve microdeletions of 1-6 nucleotides. These have resulted in 
missense and frameshift mutations only (4). This large assortment of mutations, coupled 
with the formidable size of each of these genes, makes detecting mutations and gene 
sequencing very labor intensive, expensive and technically challenging. 
Large genomic rearrangements and deletions are common features of many 
human diseases, many of which are not detected by conventional screening procedures 
(11-14). This has also been shown with BRCA1 and BRCA2. Several large germline 
deletions in BRCA1 and 1 germline deletion in BRCA2 were reportedly undetected by 
conventional genomic screening procedures (169, 172, 174). 
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Alternative methods of mutation detection have been reported for the BRCA 
genes, among others, in order to develop simple yet reliable screening procedures that 
are affordable to the general public. One commercial laboratory reported testing for 
BRCA1 using a phase test approach. This consists of an allelic-specific oligonucleotide 
assay for the 8 most common BRCA1 mutations, a protein truncation test for exon 11 
and direct sequencing of the remaining genomic regions (175). For p53 mutation 
analysis a modified nonradioactive PCR-SSCP is reported to be faster, easier and less 
expensive to perform than conventional methods, and it yields equivalent results (176). 
A potential diagnostic test for lung cancer that does not involve gene sequencing was 
also reported. This involves examining bronchial epithelial cells for loss of 
heterozygosity (LOH) (177). Loss of heterozygosity is commonly reported for BRCA1 
and BRCA2 (12, 26-30, 41, 56, 57, 70, 118-121, 149, 150). Reportedly, 88% of 
informative tumors (157-161) and 40% of sporadic tumors (162-164) show LOH for the 
BRCA loci. However, this reportedly has little clinical diagnostic value and no 
prognostic value relative to the BRCA genes (178). 
Structurally, both of these genes have much in common: a translational start-site 
for each gene is located in exon 2; exon 11 contains over 50% of the codons for the 
amino acid sequence; and both genes code for an exceptionally large, highly charged 
protein (3). 
Another feature common to most BRCA1 and BRCA2 gene mutations is that 
they produce a truncated protein as a result of prematurely introducing a stop codon in 
their amino acid sequence (8). 
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Earlier, using antibodies directed against the expected amino and carboxy 
terminals of the BRCA1 protein in surgical specimens, we were able to identify patients 
with germline BRCA1 mutations. Approximately 90% of BRCA1 mutations result in 
protein truncations. These shortened proteins do not contain a carboxy terminal. 
Individuals with only one functional allele were identified by reduced antibody 
expression of this carboxy terminal relative to antibody reactivity to their amino 
terminal. Results were confirmed with mutation analysis and DNA sequencing. 
Buccal cells were then studied as a possible minimally invasive cell source for 
this assay. Immunohistochemistry and RT-PCR for BRCA1 and BRCA2 confirmed 
transcription, translation and expression of each protein in normal human buccal cells (9, 
unpublished results). 
Here, we undertook to develop a minimally invasive, inexpensive screening test 
for BRCA protein truncations by utilizing buccal cells in an antibody-based assay. To 
accomplish this, a double-blind study of 13 highly selected, at risk individuals were 
screened for germline BRCA mutations using this antibody-based assay and mutation 
analysis and/or direct DNA sequencing of the BRCA1 and/or BRCA2 gene. 
4.3 Hypothesis 
We hypothesized that a germline BRCA1 or BRCA2 mutation resulting in a 
protein truncation would be detected in human buccal cells. 
This would be visually evident by a 50% reduction in antibody reactivity to their 
respective carboxy termini, when compared to their amino termini, for carriers of a 
germline mutation. Noncarriers would not display a reduction in antibody reactivity. 
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4.4 Objectives 
To test this hypothesis the objectives were: 1. following signed consent, collect 
buccal cells and whole blood specimens from thirteen high-risk patients for carrying a 
germline BRCA mutation; 2. Conduct a double blind study consisting of mutation 
analysis and/or direct sequencing of the BRCA1 and BRCA2 genes, and 
immunohistochemical analysis of buccal cells. 
4.5 Materials and Methods 
4.5.1 Buccal Cell Immunohistochemistry 
Following signed consent, buccal cells were collected from the oral cavity of male 
and female adult donors with cotton swabs moistened with sterile water. Cells were 
obtained by having the test subject vigorously rub the inner cheek with a cotton swab 
moistened with sterile water for approximately 20 sec. on each side. The cotton swab 
was then submerged in 500 ul of phosphate buffered saline (PBS: pH 7.5, 0.9% saline, 
0.1% crystalline grade bovine serum albumin). Cells were counted using a 
hemocytometer (Fisher Scientific Co., Pittsburgh, PA). The buccal cell sample was 
diluted to a final concentration of 32,000 cells/ml PBS. One-half milliliter of buccal cell 
solution was cytospin deposited upon Superfrost (Fisher Scientific Co., Pittsburgh, PA) 
precleaned microscope slides using a programmable cytospin (Shandon Inc., Lemer 
Laboratories, Pittsburgh, PA) centrifuge. Cells were fixed in a 50:50 acetone:methanol 
solution at -20^C for seven minutes. Air-dried slides were stored at -70^C in sealed 
boxes. Prior to immunoassay, slides were rinsed twice for 15 minutes in PBS using a 
mechanical rotator for agitation. The rinsed slides were transferred to slide trays 
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containing humidified chamber-type holders that allow the slides to lie flat so reagents 
may be deposited onto the region of each slide containing the cells. Excess PBS was 
removed from each slide using a suction pipette. Slides were then treated for 20 min. 
with blocking solution (1% BSA/PBS, 3 drops goat serum). Excess blocking solution 
was removed and one of the two primary antibodies was applied to the human BRCA1 
or BRCA2 protein. 
The 2 primary antibodies used for BRCA1 were C-20 and D-20 (Santa Cruz 
Biotechnology, Inc., CA). Each are affinity-purified, rabbit, polyclonal antibodies raised 
against a peptide corresponding to the amino acid sequence at opposite ends of the 
BRCA1 protein. The C-20 antibody corresponds to the carboxy terminus of the BRCA1 
protein and D-20 to the amino terminus. For BRCA2, primary antibodies used were two 
goat polyclonal antibodies (Santa Cruz Biotechnology, Inc.). 1-17 to the amino terminal 
and C-15 to the carboxy terminal end. No antibody cross reactivity occurs between the 
BRCA1 and BRCA2 protein antibodies. 
Antibody dilutions and immunoperoxidase assay conditions were as provided by 
the supplier. Incubation of antibody-treated sections was modified to one hour at room 
temperature followed by overnight incubation at 4 C. A biotinylated, affinity-purified, 
anti-immunoglobulin labeled antibody supplied in the Vectastain ABC Kit (Vector 
Laboratories, Inc.) was applied as a secondary antibody which binds to the primary 
antibody. Both primary and secondary antibodies were diluted with PBS to a range of 
0.5-1.0ug/ml and 5-10ug/ml, respectively. Antibody binding was demonstrated with the 
precipitation-producing chromogen di-aminobenzidine tetrahydrochloride (DAB), 
followed by hematoxylin counterstaining to display all nuclei present. 
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This produced brow regions of antibody binding. An alternate precipitant, 3-amino-9- 
ethylcarbazole (AEC), producing blue/black regions of antibody deposition, was used on 
some samples followed by an eosin counterstain according to the manufacturers’ 
supplied protocols. Coverslips were applied to treated tissue samples for microscopic 
viewing. The appearance of antibody staining on each slide containing cytospun 
deposited buccal cells was visually evaluated 3 times using an optical microscope. 
4.5.2 Mutation Analysis 
Criteria for patient selection were based on factors associated with heritable 
BRCA mutations; early age of onset, significant family history, and/or Ashkenazi Jewish 
ancestry. 
Genomic DNA was extracted using Puregene DNA Isolation Kit (Gentra 
Systems, Inc.). Briefly, cells were lysed using an anionic detergent while limiting 
enzyme activity to preserve DNA. RNA was enzymatically digested and salt 
precipitated to remove protein contaminate. Genomic DNA was then isolated by alcohol 
precipitation and resuspended in a buffered solution. Optical density was measured at 
A260 and A280 using a spectrometer on all DNA extractions to determine DNA quantity 
and purity. 
For single stranded conformational polymorphism (SSCP) analysis, polymerized 
chain reaction (PCR) amplification using genomic DNA was performed with intron- 
based primers surrounding each of 22 BRCA1 exons. Four overlapping primer sets were 
used to examine exon 11. Exons 6 and 7 were amplified as one product. PCR was 
carried out in a volume of 50ul containing lug genomic DNA, lOmM Tris-HCl (pH 8.3), 
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1.5mM MgCl2, 50mM KC1, 200uM each concentration of dATP, dTTP and dGTP, 
20uM dCTP, and luCi of labeled [32P] dCTP (6000 Ci/mmol; Amersham, Chicago). 
Each primer was 1 .OuM, and 0.4 units of Amplitaq Polymerase (Perkin Elmer Cetus, 
CT) was used in each reaction. Amplification was done using a Perkin Elmer Cetus 
9600 thermal cycler. A 46 cycle 3-temperature cycling program was used to generate 
PCR product. The program initiates with 1 minute at 95C. Cycles commence with 10 
sec. at 95C, 10 sec. at 68C, and 10 sec at 72C. This was repeated for 4 sets of 4 cycles 
with 68C descending to 60C in 2C increments every 4 cycles. When 60C was reached, 
30 cycles were repeated followed by a single 5 min. period at 72C (7). 
A modification of an SSCP protocol described by Epstein et al. (232) was used to 
detect BRCAl-gene alterations. A lul aliquot of the PCR product was diluted into 9ul of 
denaturing-loading buffer consisting of 95% formamide, lOmM NaOH, 0.05% xylene 
cyanol FF and 0.05% bromophenol blue. The lOul mixture was heated to 95C for 10 
min. and plunged into an ice bath for rapid cooling. A 3ul aliquot of this solution was 
then transferred to a 5% polyacrylamide/bis gel containing 5% glycerol and 0.5X Tris- 
borate EDTA for electrophoresis. Gels were prerun at 30 watts for 30min. before 
loading with samples. Upper and lower reservoirs of the gel apparatus contained a 0.5X 
Tris-borate EDTA buffer. 
Gels were run at room temperature for 130watt hours after which they were 
transferred to 3mm chromotography paper, placed in plastic wrap and exposed to 
reflection autoradiography film (Biomax MR film, Kodak) for 18 to 24 hours at -70C. 
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Genomic DNA sequencing was completed using the Amplicycle Sequencing Kit 
(Perkin Elmer Cetus, CT). This is a modified version of the Sanger method (235) for 
sequencing double stranded DNA (dsDNA) and does not require subcloning and/or 
extensive purification prior to sequencing. Sequencing utilized 33P isotope and was 
carried out according to the protocols supplied by Perkin Elmer Cetus. Both forward and 
reverse alleles were sequenced for each polymorphism identified by SSCP analysis to 
confirm a mutation. Reaction cycling was done in a GeneAmp PCR System 9600 
(Perkin Elmer Cetus, CA). Termination reaction cycling conditions used an initial step 
of 1 min. at 95C followed by 25 cycles of a 3-temperature cycling protocol; 30 sec. at 
95C, 30 sec. at 68C and 1 min. at 72C. Reactions were arrested by the addition of 4ul 
stop solution with the same composition as that used for SSCP. Sequencing gels 
consisted of 6% to 8% acrylamide/bis solution, IX Tris-borate EDTA and 7M urea. Gel 
solutions were passed through a micro filter prior to use. All gel glass plates were 
silonized on one side. Gels were prerun for 30 min. with IX Tris-borate EDTA buffer at 
60-75watts. Just prior to use, sequencing reactions were denatured by heating to 90-94C 
for 3 min. A 3ul sample of the denatured sequence solution was dispensed from each 
sequence reaction and loaded onto the gel. Gels were run for 2-3 hours at 60-75 watts, 
cooled, then fixed in a 10% acetic acid, 10% methanol solution for 30 min. to remove 
urea, and transferred to 3mm chromotography paper. Excess liquid was drained from the 
gel surface when removed from the solution to allow for ease of transfer. 
Gels were covered with plastic wrap, backed with a second sheet of 3mm 
chromatography paper and dried in a gel dryer model 583 (Bio-Rad Laboratories). 
Sequence ladders were resolved by autoradiographs through direct contact of dried gels 
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to Biomax MR x-ray film (Kodak, Inc. NY). Exposure time was 24-48 hours at room 
temperature. Direct BRCA2 gene sequencing was conducted by independent 
commercial laboratories at Yale University, New Haven, CT, and Mariad Genetics, Salt 
Lake City, UT. Genetic analysis of BRCA1 was confirmed by an independent 
laboratory, Retrogen, Forest Hills, CA. 
4.6 Results 
Mutation analysis of the BRCA1 gene in nine individuals revealed fifteen unique 
single stranded DNA conformational migration patterns. When sequenced, nine were 
found to be silent polymorphisms and did not change the amino acid composition of the 
BRCA1 protein. The six remaining DNA alterations were identified as mutations. 
Figure 5 shows a picture of autoradiographic results of mutation analysis using SSCP for 
these six samples. DNA sequencing in both sense and antisense direction was used to 
identify mutations. Each mutation was confirmed by identifying the complement base 
pairs for each aberrant DNA sequence, at the expected location, on the reverse sequence. 
Figures 6, 7and 8 show sequencing results for these six mutations. Both forward alleles, 
one wild type, one mutated, are shown. Additionally, the wild type allele has been 
removed from one chromatogram leaving only the mutated forward allele for viewing. 
Discriptively, these mutations consisted of two, single base conversions; C to T 
found in exon six and C to G found in exon eleven, one single base G insert located in 
exon eleven, and three large deletions identified in exons eleven, fourteen and seventeen. 
In the latter three cases, the quality and quantity of PCR product alluded to the 
possibility that a large deletion was present. In sample 10a, primers flanking exon 
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seventeen, sixteen forward and eighteen reverse, were used to amplify sufficient 
quantities of cDNA containing the suspected deletion area. For sample five, additional 
primers were also used. These primers flanked the deleted area within exon eleven and 
helped to establish an approximate location. The online DNA database sequence locator, 
known as BLAST (located at http://www.ncbi.nlm.nih.gov/blast/blast.cgi) was used to 
help place the location of the sequences on each side of the deletions. A minimum of 
fifty base pairs was used in each search. In each case, 90 -100% homology to regions of 
BRCA1 were found for each side. This helped identify the number of nucleotide bases 
that were missing from their DNA sequence. Exon eleven contained a 109 base pair 
deletion and exon fourteen was missing 144 base pairs. In the third case, all of exon 
seventeen and part of intron sixteen were removed. Part of intron sixteen was 
incorporated on both sides of exon eighteen. At the would-be splice site of exon 
seventeen and eighteen, incorporation of a small part of intron sixteen resulted in a 
frameshift and a premature stop, ten codons within exon eighteen. DNA alterations in 
each of the other five cases also resulted in the premature introduction of a stop codon 
(table 4). Each would result in a truncated BRCA1 protein product. 
Immunohistochemical analysis was also conducted on buccal cells collected from 
these nine individuals using BRCA1 and BRCA2 antibodies. Three observers recorded 
similar results during independent evaluation of immunohistochemical analysis for these 
nine samples. Six of these samples displayed a reduction of BRCA1 C-20 antibody to 
the carboxy end of the BRCA1 protein (Table 5). 
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No reduction in BRCA1 antibody reactivity was observed in the three remaining 
samples and the BRCA2 protein appeared unaltered in all nine samples (Table 5). 
Antibody reactivity was visualized by precipitant producing a red-brown color within the 
cytoplasmic region of the buccal cells that expressed BRCA protein. A reduction in 
carboxy terminal antibody reactivity was determined visually by a diminished red-brown 
color relative to the reactivity of each amino terminal. Figures 9 and 11 show typical 
results for immunohistochemical analysis of buccal cells collected from two individuals: 
figure 9, one without a BRCA1 germline mutation; figure 11, one with a BRCA1 
germline mutation. 
Identifiers were revealed and DNA analysis was compared to results of 
immunohistochemical-assay. In each case where a reduction of BRCA 1 C-20 antibody 
was recorded in buccal cells, the presence of a germline BRCA1 mutation was also 
found in the same individual. 
DNA analysis for the four remaining individuals consisted of direct sequencing 
of the BRCA1 and BRCA2 gene by a commercial laboratory. Two of these individuals 
were blood relatives. Sequencing revealed two unique germline BRCA2 mutations in 
three of these individuals. These mutations consisted of a single base deletion coupled 
with a base change in exon 16 and a single base deletion in exon 22. In each case, the 
BRCA2 alteration resulted in a frameshift in the triplet code for the amino acid sequence 
resulting in a stop codon directly after it (Table 4). 
The antibody-based assay for BRCA1 and BRCA2 protein was also applied to 
buccal cells collected from each of these four individuals. Immunohistochemical analysis 
correctly predicted the presence of a germline BRCA2 mutation in three buccal cell 
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samples. Antibody reactivity did not correlate with DNA sequencing of the fourth 
sample. Reactivity for antibodies to the BRCA1 protein appeared unaltered in all four 
samples. 
Sample 
Number DNA Analysis Mutation Characterization 
1 BRCA1 exon 14 144bp deletion, frameshift starts at codon 1462 
Amino acid sequence: expected- QTSQKSSEYPIS... 
actual- QTSQKSSELY stop 
3 BRCA1 exon 11 conversion, c to g codon 382. Stop results at codon 382 
Amino acid sequence: expected-KYQGSSVS... 
actual- KYQGSSV stop 
4 BRCA1 exon 11 single base insert g codon 284. Stop results at codon 285 
Amino acid sequence: expected- SSLQHEN... 
actual- SSLQ stop 
5 BRCA1 exon 11 109bp deletion, frameshift starts at codon 1098 
Amino acid sequence: expected- I..KQSLPGSNCKHPEI... 
actual- ..IFLEVIVR1LK stop 
6 BRCA1 exon 6 conversion, c to t codon 94. Stop results at codon 94 
Amino acid sequence: expected- CAFQLDT... 
actual- CAF stop 
7 No mutation detected 
8 BRCA2 exon 16 single base deletion/conversion; codon 2588. 
Amino acid sequence: expected- LANGGWLIPSN... 
actual- LANGGWLFLQ stop 
9 No mutation detected 
Table 4. Results of DNA analysis of the BRCA1 and BRCA2 gene for thirteen 
high-risk individuals for a germline BRCA1 or BRCA2 mutation. 
Continued next page 
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10a BRCA1 exon 17 deleted. Fifteen bases from part of intron 16 inserted 
onto the front of exon 18. Frameshift starts at codon 1691, splice site 
of exons 17 and 18. Stop results at codon 1701. 
Amino acid sequence: expected- DAEFVCERTLK... 
actual- MLSLCVNGH stop 
10b No mutation detected 
11a BRCA2 exon 22 single base deletion results in frameshift. Stop codon 
at codon 3026. 
Amino acid sequence: expected- ..ANIQLAATKKT. 
actual- ..ANIQ stop 
lib BRCA2 exon 22 single base deletion results in frameshift. Stop codon 
at codon 3026. 
Amino acid sequence: expected- ..ANIQLAATKKT... 
actual- ..ANIQ stop 
Table 4. Continued. 
Sample IMMUNOHISTOCHEMICAL ANALYSIS 
Number BRCA1 BRCA2 DNA mutation 
Amino D-20 Carboxy C-20 Amino 1-17 Carboxy C-15 analysis 
1 normal reduced normal normal germline BRCA1 
2 normal normal normal normal none found 
3 normal reduced normal normal germline BRCA1 
4 normal reduced normal normal germline BRCA1 
5 normal reduced normal normal germline BRCA1 
6 normal reduced normal normal germline BRCA1 
7 normal normal normal normal none found 
8 normal normal normal reduced germline BRCA2 
9 normal normal normal reduced none found 
10a normal reduced normal normal germline BRCA1 
10b normal normal normal normal none found 
11a normal normal normal reduced germline BRCA2 
lib normal normal normal reduced germline BRCA2 
Table 5. Results of immunohistochemical analysis of buccal cells for the BRCAland 
BRCA2 protein and mutation analysis of the BRCA1 and BRCA2 genes. Matched 
samples taken from thirteen high-risk individuals for a BRCA1 or BRCA2 germline 
mutation. 
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Figures 10 and 12 show a typical BRCA2 buccal cell assay: figure 10, one 
without a germline BRCA2 mutation; figure 12, one containing a germline BRCA2 
mutation. 
4.7 Discussion 
Increased knowledge has led to a greater understanding of the root causes and 
effects of human diseases. While the maxim, diagnosis precedes treatment, has held true 
throughout medical history, knowledge has allowed for the development of better 
techniques for detecting, identifying and treating these diseases. 
Presently, many procedures are done routinely to detect and diagnose the presence 
of certain cancers. Multiscreening serum chemistries and enzymatic tests as well as 
noninvasive procedures are used commonly for this purpose. Bone metastases are 
detected initially by elevated alkaline phosphatase and serum Ca. Gallium 67 scans are 
used to detect and stage lung cancer and lymphomas. A papanicolaou (pap) smear is 
taken to screen for cervical cancer. Prostate cancer is checked by elevated acid 
phosphatase (tartrate inhibited). Self-examination and mammography are relied upon for 
the initial detection of breast cancer. Alpha-fetoprotein levels are used to detect certain 
neoplasms such as hapatomas and testicular carcinomas. Increased fiver enzymes 
alkaline phosphatase and alanine amino transferase indicate fiver carcinomas, and other 
serum immunoglobulins are used to screen for evidence of multiple myeloma. These, 
along with ultrasonography, radiologic studies, lymphangiograms and radioisotopic 
scans are generally accepted by the public as necessary preventative and/or diagnostic 
medical procedures (234). 
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Determining an individual's genetic predisposition for one of these cancers 
however, has not been embraced by the public. The burden of expense, which is usually 
shouldered by the patient, coupled with the real and perceived risks of discrimination, 
are partially responsible for this lack of public acceptance. 
The antibody-based assay developed here, if used clinically, may help to alleviate 
some anxiety surrounding these two issues. Direct patient costs should be nominal and 
independent billing should be avoided, thus helping to ensure greater confidentiality of 
patient results and greatly reducing their out-of-pocket expenses. Also, while this assay 
may be used to determine a patient's BRCA status with surgical specimens or buccal 
cells, it should be noted that the vast majority of people are expected to test negative for 
a BRCA germline alteration. 
Still, some lack of public willingness to determine their individual genetic 
predisposition may be due to technological advances in our diagnostic capabilities. 
Relative to testing for genetic abnormalities, our ability to diagnose has outpaced our 
ability to treat patients successfully. Gene therapies hold much promise for treating 
individuals with genetic alterations that place them at risk for cancers and other diseases. 
However, these still remain treatments for the future. Therefore, while diagnosis has 
always preceded treatment, patients’ willingness to learn their potential medical needs 
for the future may be based on an equal ability to control and if necessary, change their 
predicted outcome. 
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Lane 
1 2 3 4 5 6 7 
SSCPforBRCAl exon 14. 
Sample 1 is in lane 3. 
Lane 
1 2 3 4 5 6 7 
SSCP for BRCA1 exon 11 
(partial). Sample 4 is in lane 1. 
Lane 
1 2 3 4 5 6 7 
SSCP for BRCA1 exon 6. 
Sample 6 is in lane 6. 
Lane 
1 2 3 4 5 6 7 
SSCPforBRCAl exon 11 (partial). 
Sample 3 is in lane 6. 
Lane 
1 2 3 4 5 6 7 
SSCPforBRCAl exon 11 
(partial). Sample 5 is in lane 1. 
Lane 
1 2 3 4 5 6 7 
SSCPforBRCAl exon 17. 
Sample 10a is in lane 1. 
Figure 5. Results of mutation analysis of the BRCA1 gene using single stranded 
conformational polymorphism (SSCP). Images are pictures from autoradiographs 
of selected exons of the BRCA1 gene. Lane 2 is negative control. 
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Figure 6. DNA sequencing results for samples 1 and 3 
Sample 1 Chromatograms of the BRCA1 gene exon 14, forward sequence. 
Top 2 lines, sequence of wild type allele and mutated allele. 
Bottom 2 lines, sequence of mutated allele only. 
Single 
base change 
•C7H 
Sample 3 chromatograms of the BRCA1 gene exon 11, forward sequence. 
Top, sequences of wild type and mutated allele. 
Bottom, sequence of mutated allele only. 
Deletion 
starts, 
intron 
inserted. 
Intron 
insertion 
a totga 
(stop). 
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Frameshift 
results in 'taa' 
stop codon. 
Sample 5 chromatograms of the BRCA1 gene exon 11 (partial), forward 
sequence. Top, sequence of wild type allele and allele containing deletion, 
showing where deletion occurs. Middle chromatogram, sequence 
of mutated allele. Bottom chromatogram, sequence of mutated allele showing 
insertion where frameshift results in stop codon. [ \ 
Sample 4 chromatograms of the BRCA1 gene exon 11, forward sequence, 
Sequence of wild type allele and mutated allele. 
Single nucleotide base, g, insertion. 
a 
Sample 6 chromatogramss of the BRCA1 gene exon 6 (partial), forward 
sequence. Sequence of wild type allele and allele containing 
c to t base change. Cag to tag results in stop codon. 
Figure 7. DNA sequencing results for samples 4,5 and 6. 
Intron 17 wild type allele and * Frameshift starts at exon 17/18 splice site, 
intron sixteen insertion Normal allele, first 2 codons: at get. 
Sample 10a chromatograms of the BRCA1 gene exon 18 (partial), forward sequence. 
Top, sequence of wild type allele and allele containing intron 16 insertion. 
Bottom sequence shows insertion sequence. Insertion results in frameshift at exon 17/18 splice site. 
Figure 8. DNA sequencing results for sample 10a. 
Figure 9. BRCA1 immunohistochemical analysis in normal human buccal cells. 
No reduction in D-20 or C-20 antibody reactivity. Red-brown coloration within cells is 
indicative of antibody reactivity. Left, D-20 antibody reactivity to the amino end of the 
BRCA1 protein. Right, C-20 antibody reactivity to the carboxy end of the BRCA1 protein. 
Figure 10. BRCA2 immunohistochemical analysis in normal human buccal cells. 
No reduction in 1-17 or C-15 antibody reactivity. Red-brown coloration within cells. 
Left, 1-17 antibody reactivity to the amino end of the BRCA2 protein. 
Right, C-15 antibody reactivity to the carboxy end of the BRCA2 protein. 
Figure 11. BRCA1 immunohistochemical analysis in human buccal cells with a BRCAl 
germline mutation. Red-brown coloration within cells is indicative of antibody reactivity. 
Left, D-20 antibody reactivity to the amino end of the BRCAl protein. Right, C-20 antibody 
reactivity to the carboxy end of the BRCAl protein. No reduction in D-20 antibody reactivity, 
reduced C-20 antibody reactivity. 
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Figure 12. BRCA2 immunohistochemical analysis in human buccal cells with a 
BRCA2 germline mutation. Red-brown coloration within cells is indicative 
of antibody reactivity. Left, 1-17 antibody reactivity to the amino end of the 
BRCA1 protein. Right, C-15 antibody reactivity to the carboxy end of the BRCA2 
protein. No reduction in 1-17 antibody reactivity, reduced C-15 antibody reactivity. 
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